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INTRODUCTION 
1.1  FLAVIVIRUS 
The genus Flavivirus of the family Flaviviridae comprises over 70 viruses, 
many of which, such as the Dengue (DEN) virus, Japanese Encephalitis (JE) virus, 
West Nile virus (WNV), St. Louis Encephalitis (SLE) virus, and Yellow fever (YF) 
virus are important human pathogens1,2.  Flavivirus can be transmitted to humans via 
either a mosquito or tick vector. The flavivirus genera are of importance to the 
medical community because they have been found to be the causative agent of many 
endemic and epidemic illnesses across the world. Japanese Encephalitis virus (JEV) 
is the most important cause of viral encephalitis in Asia based on its frequency and 
severity. With the near eradication of poliomyelitis, JEV is now the leading cause of 
childhood viral neurological infection and disability in Asia3. 
 Dengue and its severe and sometimes fatal forms, Dengue hemorrhagic 
fever and Dengue shock syndrome, alone affect nearly 80 million people a year4. As 
demonstrated in recent out breaks of meningitis by West Nile (WN) virus in Algeria 
and Romania, viruses of this group sometimes cause serious public health concern in 
unexpected locations5. 
 The first flavivirus discovered to infect human was the Yellow Fever virus, 
which led to the descriptive naming of this entire family of these viruses6,7. The 
family was subsequently named “means “yellow” in Latin after the associated 
jaundice that occurs during infection 8. Since their discovery, the flavivirus persist as 
causative agents for a wide range of infectious diseases worldwide. However, the 
most common causes of disease are associated with Japanese Encephalitis group 
viruses within the flavivirus genus9,10,11.  
 There are over 70 various flavivirus species, but not all of them are known to 
cause human disease. Many time, an individual may be infected with one of these 
flavivirus species and not even be aware, as an asymptomatic infections are common 
in regard to flavivirus infections. Severe infection of certain flaviviruses can lead to 
serious complications, such as inflammation of the brain, hemorrhage and death. 
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Most of the flavivirus species cause acute encephalitis syndrome in human. The 
flaviviruses include Japanese Encephalitis virus (JEV) Dengue virus (DENV) and 
West Nile Virus (WNV) which are the main cause of encephalitis in human12. 
The epidemiology of flavivirus encephalitis is governed by a complex 
interplay of climatic, entomologic, human behavioural, viral, host factors that are not 
completely understood and the virus is transmitted naturally among birds in enzootic 
cycles by bird biting mosquitoes especially the Culex genus. Humans become 
infected inadvertently when they encroach on this cycle, but they are considered 
“dead-end” hosts because normally they do not have sufficiently high or prolonged 
viraemia to transmit the virus further. In Asia, pigs as well as birds are important 
natural hosts for Japanese Encephalitis virus, since these animals are often kept close 
to human dwellings they serve as amplifying or bridging hosts that transmit the virus 
to humans 13.  
 Japanese Encephalitis mostly occurs in areas of South Asia, South East Asia, 
and  the  Pacific  with  transmission  of  the  disease  likely  to  increase  in  Bangladesh,  
Cambodia, Indonesia, Laos, Myanmar, North Korea, and Pakistan5,14,15. The burden 
of DF and DHF disease is not very well documented, however in 1998 alone, more 
than 1.2 million cases were reported to the World Health Organization, with South 
East Asia, the Western Pacific and more recently the Americas being the most 
affected regions16. West Nile virus is of public health importance and has a wide 
geographical range that includes portions of New York, Romania Russia Israel17. 
 The first outbreak of DHF was recorded in 1963 in Kolkata,18 since Dengue 
spreads to all parts of India19. The first outbreak of JE occurred in Pondicherry and 
Vellore (Tamil Nadu)20 in South India in 1955 and later spread all over the country, 
including Haryana state in North India21. The West Nile virus was first characterized 
in several outbreaks in the Mediterranean basin in the early 1950s and 1960s22. 
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National Status of AES in India 
The incidence of acute encephalitis syndrome (AES) has been reported 
worldwide. Viruses are the most common causative agents of AES, though bacteria, 
fungi, parasites, and toxins have also been implicated in its etiology. The incidence 
of AES varies from 0.9 per 100,000 adults in Nigeria, to 185 per 100,000 adults for 
a rural population in Nepal during an outbreak of Japanese Encephalitis (JE)23.  
In India, it has been estimated that a population of 375 million people 
residing in 171 endemic districts of 17 states are at a risk of acquiring AES24. 
Approximately  70%  of  the  disease  burden  is  from  the  Northern  State  of  Uttar  
Pradesh (UP), which has become an epicentre for this killer disease. In the year 2012 
alone, 3,494 patients suffering from AES were admitted to different government 
hospitals of Gorakhpur and Basti divisions, 588 of who died25.  
Japanese Encephalitis virus (JEV) has been the major and consistent 
causative agent of AES in UP, annually accounting for approximately 10–15 yrs of 
the patients26. The growth of vector mosquito population is favoured by the 
accumulation of water and extensive rice cultivation in the Terai region of Eastern 
UP  and  other  adjoining  regions  that  run  parallel  to  the  lower  ranges  of  the  
Himalayas. Besides JEV, other viruses that have contributed to the high incidence of 
AES in India include the Dengue virus (DV), Enterovirus, Herpes simplex virus 
(HSV), Measles virus and Chandipura virus27 however, the aetiology of AES 
remains unknown in 68–75% of the patients. An accurate identification of the 
organism causing AES is essential for surveillance and patient management because 
some of these infections are preventable or treatable. 
AES outbreaks often have a high mortality and hence are a major public 
health concern in India. Since the first major reported outbreak of AES from Eastern 
India (Bankura, West Bengal) in 197328,29 parts of the country have been devastated 
by numerous outbreaks with striking regularity. The surveillance for sporadic cases 
of AES has been limited. Subsequent to early studies from Lucknow (1957–58)30 
and Vellore (1960–61)31, the Indian Council of Medical Research initiated JEV 
surveillance in many parts of the country, focusing on mosquito-borne viruses. In 
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these studies, investigators conducted serological tests and isolated viruses, 
collecting zoonotic and entomological evidence with an eye towards finding JEV as 
the  aetiological  agent.  Surveillance  studies  conducted  in  the  same regions  that  had  
experienced prior AES outbreaks reported about one-quarter to one-half of all cases 
to be seropositive for IgM antibodies against JEV32-34.  
As a result, most outbreaks are presumptively attributed to JEV, before any 
investigations are initiated. In recent years, investigations into large outbreaks of 
AES have been negative for JEV (or a flavivirus). Instead outbreaks were found to 
be due to Rhabdovirus (Chandipura virus)35 or water-borne enteroviruses. These 
outbreaks have also occurred in hot and humid seasons, have predominantly affected 
children, and have had a high case-fatality. Surveillance studies conducted in inter-
epidemic period have also found other aetiologies. It needs to be emphasized that in 
the absence of a definite viral diagnosis, other predictors of aetiology such as 
clinical features, seasonality and prognosis may not be able to distinguish between 
aetiologies. While viral diagnosis is tedious, expensive and may not be possible for 
individual patients, it must be done periodically at population levels to record 
epidemiological shifts. 
Several factors might account for enteroviruses replacing JEV as the major 
cause of AES. First, JE vaccination campaigns, launched in endemic districts, may 
have brought about this shift. According to a recent systematic review of AES 
surveillance studies globally, 2 JE vaccination programmes in developing countries 
reduce the incidence of JE and bridge the gap between the incidence of AES in 
developed and developing countries. This observation is supported by 
epidemiological data which show that the introduction of JE vaccination in endemic 
regions reduced the overall incidence of AES36.  
Second,  it  is  likely  that  once  the  incidence  of  JE  falls  either  due  to  
vaccination  or  due  to  periodic  fluctuations  in  the  circulation  of  JEV  or  its  vector,  
AES caused by other neuropathogenic aetiological agents are ‘unmasked’, although 
at a much lower incidence. Advances in molecular diagnostics, viral culture and 
isolation, as well as use of an extended panel of tests for potential aetiological agents 
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could be other factors leading to increased frequency of identification of alternative 
aetiologies. 
The emergence of non-JEV aetiologies in outbreaks and surveillance studies 
directly impacts preventive measures for AES. While vector control programmes 
and JEV vaccination remain important strategies, the presence of other agents calls 
for designing and implementing novel preventive strategies that would focus on 
containment of water-borne enteroviruses and vectors for Chandipura virus. This 
will need a multisector approach involving health, water resources, sanitation and 
rural development departments. Recently the thought process on such an approach 
has been initiated37.  
In addition, need to move from JE surveillance to surveillance for the entire 
spectrum of AES, so that evidence based public health actions can be planned and 
carried out. While this review is based on a thorough search of the literature, it has 
certain limitations. Publication bias is a major limitation because studies with 
negative or uncertain aetiological outcome might not have been published in 
biomedical journals. Such technical reports and unpublished documents from 
national and regional disease control organizations often do not find their way to 
scientific journals.  
 Second, earlier researchers seldom used a battery of tests that would include 
all possible viruses causing AES. Not only did the studies lack consistency, they 
also differed from one another in respect to the viral diagnostic methods employed, 
and the range of aetiologies for which diagnostic tests were included. For example, 
researchers investigating outbreaks of AES were more likely to look for JEV if this 
virus was also reported from the same region in the past. Third, big outbreaks are 
more likely to be investigated and reported, and surveillance studies are more likely 
to be conducted, because they are more likely to impact public health. Lastly, in the 
recent past India has seen epidemics of Chikungunya and Dengue, which mostly 
present as fever-arthralgia and fever-rash, respectively. 
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AIM AND OBJECTIVE 
AIM 
1. Seroprevalence of antibodies to flaviviruses in the population of Tamil Nadu. 
2. Screening of AES patients for flavivirus etiology by RT-PCR. 
3. Genetic characterization of the positive samples. 
4. Sequencing and Phylogenetic analysis of circulating strains.  
5. Development and Standardization of pan-flavivirus detection system 
(ELISA) using peptide antigen to enable early and economical detection of 
flavivirus infection. 
OBJECTIVE 
 Dengue, Japanese Encephalitis and West Nile encephalitis, are the common 
viral diseases associated with high morbidity and mortality. There is not much data 
available on the seroprevalence of the flavivirus antibodies in the population of 
Tamil Nadu. A seroprevalence study will give us a clear picture about the exposure 
of the population to flavivirus. 
 The initial symptoms of most of the viral infections are similar to each other 
as  well  as  to  some  other  viral  diseases.  Making  clinical  diagnosis,  therefore,  
becomes a challenging task for the clinician. Several studies have been reported on 
using detection of serum antibodies against flavivirus and the use of specific primers 
for the diagnosis of flaviviral  disease.  The use of RT-PCR and ELISA will  help to 
detect the early infection and also if the sample is collected after a week time, thus 
giving us an accurate picture about the prevalence of flaviviruses. 
  Genetic analysis of the flavivirus will help us to understand the etiology of 
the circulating strains. The phylogenetic analysis will reveal the circulating 
genotypes of the flavivirus11. Given that virus genetic diversity may influence 
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disease severity, the phylogenetic analysis will help in assessing the severity of the 
disease that the strain will cause and will help in taking precautionary measures. 
 Several diagnostic systems are available for the detection of circulating 
antibodies in patients serum. However, no gold standard is available for 
immunological diagnosis of flaviviruses. A field based simple method to use  
pan-flavivirus detection (ELISA) system may be of great help specifically for low 
endemic areas to differentiate flavivirus infections from other viral infections(26). 
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REVIEW OF LITERATURE 
3.1 FLAVIVIRUS 
Virus is an intra cellular parasite and classified as animal virus and plant 
virus. It is replicated by lytic cycle and lysogenic cycle in host cell. The AES case 
mainly denotes either by infected viruses JE, Dengue, West Nile. All these 3 viruses 
come under the flavivirus. The flavivirus genus comes from the flaviviridea family 
of viruses, which are classified as arthropod-borne viruses. Flavivirus species can be 
transmitted to humans via either a mosquito or tick vector. They are (+)-sense, 
single stranded RNA icosahedral viruses that are surrounded by an envelope (Figure 
3.1).  All flavivirus are similar in size, ranging from about 40-65 nm. Flaviviruses 
also share a common genome size of about 9500-12500 nucleotides38,39. The 
flavivirus genera are of importance to the medical community because they have 
been found to be the causative agent of many endemic and epidemic illnesses across 
the world. 
 
Figure 3.1 
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3.1.1 Structure of Japanese Encephalitis virus 
 
The causative agent Japanese Encephalitis virus is an enveloped virus of the 
genus flavivirus. The positive sense single stranded  RNA genome is packaged in 
the capsid which is formed by the capsid protein. The outer envelope is formed by 
envelope (E) protein and is the protective antigen. It aids in entry of the virus to the 
inside of the cell. The genome also encodes several nonstructural proteins also (NS1, 
NS2a, NS2b, NS3, N4a, NS4b, NS5) (Figure 3.2). NS1 is produced as secretary 
form also. NS3 is putative helices, and NS5 is the viral polymerase. It has been 
noted that the Japanese Encephalitis virus (JEV) infects the  lumen of the  
endoplasmic reticulum (ER) and rapidly accumulates substantial amounts of viral 
proteins for the JEV40,41. 
 
Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2 Structure of Dengue virus 
 
Genome of Dengue virus is enveloped, spherical, about 40-50 nm in 
diameter contains about 11,000  nucleotide bases, which  code for the three different 
types  of  protein  molecules  (C,  prM  and  E)  that  form  the  virus  particle  and  seven  
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other types of protein molecules (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5) that 
are only found in infected host cells and are required for replication of the virus 
(Figure 3.3). It is a Monopartite, linear, ssRNA (+) genome of about 10-12 kb and 
spherical nucleocapsid lipid bilayer envelope. Replication occurs in cytoplasm. Have 
four serotypes (DEN-1, 2, 3, 4). All four serotypes can cause severe and fatal 
disease. There is genetic variation within each of the four serotypes42. 
 
Figure 3.3 

 
3.1.3 Structure of West Nile Virus  
West Nile virus (WNV) is a mosquito-borne zoonotic arbovirus belonging to 
the genus flavivirus in the family flaviviridae. Image reconstructions and 
cryoelectron microscopy reveal a 45–50 nm virions covered with a relatively smooth 
protein surface. This structure is similar to the Dengue virus. The genetic material of 
WNV is a  positive-sense, single strand of  RNA, which is between 11,000 and 
12,000 nucleotides long; these  genes encode seven nonstructural proteins and three 
structural proteins (Figure 3.4). The RNA strand is held within a nucleocapsid 
formed from 12-kDa protein blocks, the capsid is contained within a host-derived  
membrane altered by two viral  glycoproteins43. 
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Figure 3.4 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 LIFE CYCLE OF FLAVIVIRUS 
 
Viruses belonging to the family flaviviridae are considered class 4 viruses 
within the Baltimore classification scheme. Viruses in this class are positive sense, 
single stranded RNA viruses which replicate their genome through a partially 
double-stranded intermediate form. The following sections address the life-cycle of 
viridae specifically, but they still fall close to the generic category of class 4 viruses 
(Figure 3.5). The structural organization of flaviviruses and their structural proteins 
has provided insight into the molecular transitions that occur during the viral life 
cycle and their stages are virus attachment, entry, and uncoating these section 
overviews the proteins important to a flavivirus tissue tropism, the method used for 
entering the cell and the strategies used for signaling viral uncoating. Expression and 
Biosysnthesis, the various genes of the generic flavivirus genome and the timing 
related to each gene44. 
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Methods of Transmission 
 There are four categories of ecological and genomic division for flavivirus. 
Two of these groups use the mosquito as their transmission vector. As stated in the  
vaccine section, almost half of all flaviviruses use the mosquito vector for 
transmission. Another group is founded by the flaviviruses using ticks as their 
vectors, and a final group represents the flaviviruses without a (known) vector. 
Viruses use only invertebrates as their transmission vectors and how flaviviruses 
infect primarily vertebrates. Flaviviruses are grouped separate from other 
flaviviridae because  of  this  peculiarity  that  is,  the  ability  to  infect  vertebrates  and  
invertebrates as well as their strange methods of transmission45. 
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3.3.1 Transmission of Japanese Encephalitis Virus (JEV)  
The  vertical  transmission  of  JEV  refers  to  transmission  of  the  virus  to  the  
next generation of mosquitoes. Vertical transmission probably occurs at oviposition 
rather than transovarially which might account for the persistence of virus  
in nature46. Vertical transmission of JEV has been reported in 3 strains  
of C. tritaeniorrhynchus, C. Pipiens, Aedes albopictus, A. togoi, C. annulus,  
C. quinquefasciatus and Armigeres subalbatus mosquitoes.  
A high prevalence of JEV antibodies has been documented in pigs, horses 
and birds and to a lesser extent in cattle, sheep, dogs and monkeys. Pigs and ardecid 
birds are the most important hosts for maintenance, amplification and spread of JEV. 
Pigs are the main component in the transmission cycle with respect to human 
infection whereas herons, egrets and other ardeid birds are important maintenance 
hosts. JEV infected animals and mosquitoes generally remain asymptomatic, 
although fatal encephalitis occurs in horses and fetal wastage occurs in swines47. 
These effects on domestic animals have lead to the development of animal vaccines. 
The domestic animals can get infected but show no evidence of viremia. Rodents 
appear to be unimportant hosts48. Amphibians, reptiles and bats can become infected 
experimentally  and  the  virus  can  persist.  Pigs  are  the  most  important  reservoir  of  
JEV because of the following reasons: 
(1) High incidence of natural swine infection. 
(2) High frequency of viremia in pigs after infected mosquito bite. 
(3) Viremia lasting in high titre for 2–4 days which is adequate to infect C. 
tritaeniorrhynchus. 
(4) Transmission of JEV from pig to pig by laboratory reared C. tritaeniorrhynchus 
(5) Large number of C. tritaeniorrhynchus mosquitoes found biting pigs in 
nature. 
(6) Presence of large number of susceptible pigs is replenished each year due to 
commercial slaughtering of the animals at 10–16 months of age49. 
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Figure 3.6: Transmission of JEV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Transmission of Dengue Virus 
Susceptible human become infected after being bitten by an infected female 
Aedes aegypti mosquito. Viremia in humans beings toward the end of 4-6 days 
incubation period and persists until fever abates, which is typically 3-7 days. An 
uninfected Ades mosquito may acquire the virus after feeding during this viremic 
period. The mosquito has an incubation period 8-12 days before it is capable of 
transmitting the virus to susceptible individuals. Once infected, mosquito carry the 
virus for their life span and remain infective for humans50,51. 
The part of the transmission cycle that takes place within the human body.  
1. The virus is inoculated into humans with the mosquito saliva. 
2. The virus localizes and replicates in various target organs, for example, local 
lymph nodes and the liver.  
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3. The virus is then released from these tissues and spreads through the blood 
to infect white blood cells and other lymphatic tissues.  
4. The virus is then released from these tissues and circulates in the blood.  
The part of the transmission cycle that takes place within the mosquito. 
1. The mosquito ingests blood containing the virus.  
2. The virus replicates in the mosquito midget, the ovaries, nerve tissue and fat 
body. It then escapes into the body cavity, and later infects the salivary 
glands.  
3. The  virus  replicates  in  the  salivary  glands  and  when  the  mosquito  bites  
another human, the cycle continues.  
 
Figure 3.7: Transmission of Dengue virus 
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3.3.3 Transmission of West Nile Virus  
The arboviral like WNV are maintained in complex life cycles involving a 
non-human primary vertebrate host, usually birds, and a primary arthropod vector. 
Transmission occurs between susceptible vertebrate hosts by Clulicids (blood 
feeding arthropod mosquitoes), Phelbotomids (sand flies), Ceratopogonids (‘no-se-
ums’), Loxodids (hard ticks) and Argasids (soft ticks)52-55. Humans, domestic and 
wild mammals can develop clinical illness and die but usually are incidental or 
“dead  end”  hosts,  meaning  that  they  contribute  little,  if  at  all  to  the  spread  of  the  
virus. The reservoir for this virus is a bird, and a recent study suggests the Picuris 
Ground Doves and Shiny Cowbirds both serve as reservoirs, but the former 
produces 10 times as many infectious mosquitoes than the later. Humans are not the 
only one vulnerable to this virus. WNV can also infect domestic animals (cats and 
dogs), horses, and even bats, squirrels, and rabbits (with less frequency). 
 
Figure 3.8: Transmission of West Nile virus 
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Birds with severe infections suffer high morbidity and mortality rates, but 
typically develop life-long immunity after exposure and a short viremia. Mosquitoes 
acquire the virus when they feed on the infected reservoir birds. Many mammals, 
including humans and horses, are incidental hosts that become infected when fed 
upon by an infected mosquito. Although mammals do not develop levels of viremia 
sufficient to infect mosquitoes, and thus cannot serve as reservoirs, infections in 
mammals may result in severe, potentially fatal meningoencephalitis. The incubation 
period of WNV ranges from 2-14 days. Of all people infected with WNV, most will 
not  be  aware  of  the  infection  and  will  clear  it  with  no  symptoms,  80% of  infected  
individuals did not develop symptoms42.  
3.4 VECTORS 
Another way that a disease agent can be introduced is by introduction of an 
infected vector. Vectors may be either biological vectors that are persistently 
infected and allow the pathogen to develop and reproduce, or mechanical vectors on 
which the pathogen resides for a short period of time. Because they are persistently 
infected, biological vectors are more likely to introduce exotic disease agents of 
animals to new areas than are mechanical vectors. 
3.4.1 Vectors for Japanese Encephalitis 
The vectors of JEV are Culex tritaeniorhynchus, Culex vishnui, Culex 
pseudovishnui, Culex gelidus, Culex fuscocephala, Culex quinquefasciatus, Culex 
pipienspallens, Culex bitaeniorhynchus, Culex annulirostris, Aedes togoi,  
Ae. japonicus, Ae. desvexansnipponii, Anopheles annularis and An. vagus. Culex 
tritaeniorhynchus is in the tritaeniorhynchus complex, breeds in rice fields, ground 
pools in vast areas. Two types of mating behavior, eurygamy and moderate 
stenogamy were detected. In the case of the eurygamy type, the mosquitoes were 
from Southern Thailand and hilly areas near Kanchanaburi, Thailand56.  
Female  mosquitoes  are  usually  dark  in  color,  the  cibarial  armature  has  rod  
teeth and the posterior end of the cibarial armature is bowl shaped with a typical rim. 
The rim of the bowl is everted. The moderate stenogamy type were mosquitoes from 
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the plain areas such as Bangkok, Ayutthaya, SuphanBuri and Saraburi. The posterior 
end of the cibarial armature is bowl shaped with a stout rim. The larvae were 
characteristic in their siphon index, antennal index, hair of prothoracic segment and 
comb scale number and arrangement. Cx. tritaeniorhynchus summorosus from 
Japan, Los Banos and Luzon, Philippines, differed from Cx. tritaeniorhynchus in 
that on the lateral plate of the phallosome tritaeniorhynchus teeth are somewhat 
weakly developed and only gently curved whereas in tritaeniorhynchus summorosus 
they are strongly developed, considerably longer, and sharply recurved56.  
3.4.2 Vector for Dengue virus 
The most common epidemic vector of Dengue in the world is the Aedes 
aegypti mosquito. It can be identified by the white bands or scale patterns on its legs 
and thorax. Dengue is transmitted by an infected female mosquito. Aedes aegyptiis 
primarily a day time feeder and mainly bites in the morning or late in the afternoon 
in  covered  areas.  Therefore,  this  mosquito  does  not  tend  to  bite  at  the  beach  on  a  
sunny day. It is also not usually found in tropical forests or mangroves, except in 
Africa. The Aedes aegypti female prefers to lay its eggs in artificial, rather than 
natural containers that have fairly clean water and are located around human 
habitation57. Aedes aegypti currently distributed in urban areas throughout the 
tropical regions of Africa, Asia, Australia, South pacific, America, the origin of the 
species is considered to be Africa58. 
3.4.3 Vector for West Nile virus 
Birds act as both carriers and amplifying hosts of WN virus in nature. 
Ornithophilic mosquitoes belonging mainly to Culex species act as vectors for 
transmission of infection from viremic birds to a large spectrum of vertebrate hosts. 
Culex univittatus complex  (South  Africa,  Israel),  Culex modestus (France), Culex 
vishnui complex (India and Pakistan), Culex pipens (Romania, USA) acts as major 
vectors of WN virus. There is no evidence to suggest person-to-person/animal, or 
animal to animal/person transmission. The virus multiplies in the mosquito vector 
and after an extrinsic incubation period of about 2 weeks, the vector becomes 
infective for active transmission to a susceptible host. Hibernating mosquitoes can 
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carry the virus59,60  and vertical transmission of the virus from infected female to her 
progeny has been reported61. Migratory birds play a major role in the WN virus 
dissemination. However, virus dissemination through infected mosquitoes or by 
illegally imported infected pet birds should also be considered a possibility. 
The West Nile virus maintains itself in nature by cycling between 
mosquitoes and certain species of birds. A mosquito (the vector) bites an uninfected 
bird (the host), the virus amplifies within the bird, and an uninfected mosquito bites 
the bird and is in turn infected. Other species such as humans and horses are 
incidental infections, as they are not the mosquitoes preferred  blood meal source. 
The  virus  does  not  amplify  within  these  species  and  they  are  known  as  dead-end  
hosts. 
3.5 CLINICAL FEATURES 
3.5.1 Clinical features of Japanese Encephalitis virus 
Most JEV infections in humans do not result in apparent illness. The 
epidemiological data an asymptomatic and symptomatic infection are limited and 
may vary in different regions. The estimated ratio of symptomatic to asymptomatic 
infection varies from 1 in 25 to 1 in 100062.   
The incubation period of JEV is 5–15 days. The clinical syndrome varies 
from a nonspecific febrile illness to aseptic meningitis to severe encephalitis. Most 
JE patients are associated with acute short-lived illness followed by prolonged 
convalescence. Following 2–4 days of nonspecific illness, the patient develops 
headache, fever and rigor. The gastrointestinal symptoms include nausea, anorexia, 
vomiting and diffuse abdominal pain which improve in a few days from the date of 
illness. 
  During the acute stage of encephalitis, seizures have been reported by 
various investigators and the frequency ranges from 6.7 to 67.2%63-67. The seizures 
may be focal or secondary generalized and rarely may be associated with status 
epilepticus. Seizures are more common in children compared to adults. 
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JE  is  actually  an  encephalomyelitis,  patients  with  JE  may  manifest  with  
variable focal lower motor neuron signs, which may be as subtle as focal reflex loss 
or as severe as flaccid quadriplegia followed by wasting. Acute flaccid weakness in 
JE has been reported in 5–20% patients68,69.  JEV is transmitted through a zoonotic 
cycle between mosquitoes, pigs and water birds. Human get accidentally infected 
when bitten by an infected mosquito and are a dead end host. 
3.5.2 Clinical features of Dengue virus 
The incubation period is 3-14 days (average, 4-7 days) symptoms that begin 
more than two weeks after a person departs from an endemic area are probably not 
due to Dengue. Many patients experience a prodrome of chills, erythematous 
mottling of the skin, and facial flushing (a sensitive and specific indicator of Dengue 
fever). The prodrome may last for 2-3 days. Children younger than 15 years usually 
have a nonspecific febrile syndrome, which may be accompanied by a 
maculopapular rash70.  
Classic  Dengue  fever  begins  with  sudden  onset  of  fever,  chills,  and  severe  
(termed break bone) aching of the head, back, and extremities, as well as other 
symptoms. The fever lasts 2-7 days and may reach 41°C. Fever that lasts longer than 
10 days is probably not due to Dengue. Rash in Dengue fever is a maculopapular or 
macular confluent rash over the face, thorax, and flexor are surfaces, with islands of 
skin sparing. The rash typically begins on day 3 and persists 2-3 days. Fever 
typically abates with the cessation of viraemia70. 
 The convalescent phase may last for 2 weeks. Patients are at risk for 
development of Dengue hemorrhagic fever or Dengue shock syndrome at 
approximately the time of effervescence. Abdominal pain in conjunction with 
restlessness, change in mental status, hypothermia, and a drop in the platelet count 
presages the development of Dengue hemorrhagic fever. 
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3.5.3 Clinical features of West Nile virus 
The typical case of West Nile virus were characterized by fever, headache, 
generalized myalgia, vomiting, diarrhea, and anorexia71. The course of fever may be 
biphasic. Rash occurs in about half of cases with onset either during the febrile 
phase  or  at  the  end  of  it.  The  rash  is  roseolar  or  maculopapular,  nonirritating,  and  
involves the chest, back, and upper extremities. Rash may persist for upto one week 
and resolves without any desquamation. Generalized lymphadenopathy is a common 
finding. Pharingitis and gastrointestinal symptoms may occur. Hepatitis, 
Pancreatitis, myocarditis, cardiac dysrhythmia, rhabdomyolysis, orchitis, uveitis 
vitreous, optic neuritis, and chorioretinitis have been reported72-75. In the Central 
African Republic, WNV has been responsible for cases of hepatitis, including fatal 
disease resembling Yellow Fever (YF)75.  
The risk of severe neurologic disease is higher among patients older than  
50 years of age and among organ transplant recipients who are 
immunocompromised54. Approximately 50% of persons with neuroinvasive disease 
will have persistent sequelae 12 months after infection. CDC reports that when the 
central nervous system (CNS) is affected clinical syndromes ranging from febrile 
headache to aseptic meningitis to encephalitis may occur, and these are usually 
indistinguishable from similar syndromes caused by other viruses. About 60 - 75% 
of people with neuroinvasive WNV infection reportedly have encephalitis or 
meningoencephalitis, which is characterized by altered mental status or focal 
neurologic findings. About 25 to 35% of people with neuroinvasive WNV infection 
reportedly have meningitis without evidence of 12 encephalitis. WN meningitis 
usually involves fever, headache, and stiff neck. Pleocytosis is present. Changes in 
consciousness are not usually seen and are mild when present.  
3.6 PATHOGENESIS 
3.6.1 Pathogenesis of Japanese Encephalitis virus 
Crossing the blood–brain barrier is an important factor in the increased 
pathogenesis and clinical outcome of the neurotropic viral infection. After entering 
the body through a mosquito bite, the virus reaches the central nervous system 
33 
 
(CNS) via leukocytes (probably T lymphocytes), where JEV virions then bind to the 
endothelial surface of the CNS and are internalized by endocytosis. Macrophage and 
axonal transport may play a critical role in JEV pathogenesis. However, convincing 
evidence is still lacking76-80. 
JE typically develops in patients after an incubation period of 5–15 days. It is 
possible that during this time, the virus resides and multiplies within host 
leukocytes, which act as carriers to the CNS. T lymphocytes and IgM play a major 
role in the recovery and clearance of the virus after infection78.  
A plausible therapy of clearing the virus load while in its incubation period 
in peripheral lymphatic tissues and spleen may actually prevent JEV pathogenesis. 
The molecular pathogenesis of JEV infection is still unclear. Reports suggest that 
JEV infection affects neuronal progenitor cells (NPCs) in the sub ventricular zone 
and severely compromises their ability to proliferate. JEV infection does not result 
in  the  death  of  resilient  NPCs,  but  the  cycling  ability  of  these  cells  is  suppressed.  
This arrested growth and proliferation of NPCs might be the cause of neurological 
consequences in children infected by JEV81-85. Also, there are reports that JE can be 
transmitted  transplacental  by  which  means  the  virus  could  affect  the  normal  
neuronal development of the fetus86. 
3.6.2 Pathogenesis of Dengue virus 
After inoculation the virus replicates in nearby lymph node cells. Viremia 
follows and reticuloendothelial cells in skin and other tissues grow to be infected. 
Local inflammatory changes happen around tiny vessels in the skin87. Dengue 
hemorrhagic fever occurs in kids who have previously been exposed to infection 
with a diverse serotype of the virus, or who have acquired antibody passively from 
their mother. 
The  incubation  period  is  about  7  days  prior  to  the  onset  of  high  fever,  
headache, eye pains, backache and chills. Limb pain is often severe in Dengue and 
this gives rise to its common name, break bone fever. A blanching erythematous 
macular rash may appear on the third or fourth day of the illness. Lymphadenopathy 
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could be present. Encephalopathy, cardiomyopathy and liver damage also occur. 
Leucopenia is usual in the peripheral blood. In Dengue hemorrhagic fever the patient 
is far more ill, and blood pressure falls as a result of transudation of fluid from the 
vascular compartment60,88-91. 
This fluid can accumulate in the abdominal cavity or in the pleural spaces. 
There  might  be  spontaneous  bleeding  into  the  skin  and  at  other  sites.  The  loss  of  
circulating blood volume causes shock, with low blood pressure, rapid pulse, 
restlessness and abdominal discomfort (the Dengue shock syndrome), which can 
have a mortality of 50% if untreated87,70. 
Molecular studies have demonstrated that Dengue viruses vary genetically in 
nature unfortunately, phenotypic changes that have been observed in the field have 
not yet been associated with genetic changes in the virus. The viral factors play a 
significant role in the pathogenesis of severe Dengue disease92-97. 
3.6.3 Pathogenesis of West Nile virus 
The mechanism by which WNV and other neurotropic viruses cause the 
blood-brain barrier (BBB) remain largely unknown, although tumor necrosis factor 
alpha (TNF-Į)-mediated changes in endothelial cell permeability may facilitate 
central nervous system (CNS) entry. It is likely that WNV infects the CNS at least in 
part via hematogeneous spread, as an increased viral burden in serum correlates with 
earlier viral entry into the brain98-100.  
Additional mechanisms may contribute to WNV CNS infection, including 
infection or passive transport through the endothelium or choroid plexus epithelial 
cells102 infection of olfactory neurons and spread to the olfactory bulb103 direct 
axonal retrograde transport from infected peripheral neurons104,105. Although the 
precise mechanisms of WNV CNS entry in humans require additional study, 
changes in cytokine levels that may modulate BBB permeability and infection of 
blood monocytes and choroid plexus cells have been documented in animal 
models101,106,99.  
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Infection or passive transport trough the endothelium or choroid plexus 
epithelial cells. Infection of olfactory neurons and spread to the olfactory bulb. A 
“Trojan horse” mechanism in which the virus is transported by infects immune cells 
that traffic to the CNS101. 
Direct axonal retrograde transport from infected peripheral neurons. 
Although the precise mechanisms of WNV CNS entry in humans require additional 
study, changes in cytokine levels that may modulate BBB permeability and infection 
of blood monocyte and choroid plexus cells have been documented in animal 
models101,104. 
3.7 EPIDEMIOLOGY 
3.7.1 Epidemiology of Japanese Encephalitis virus 
The epidemic of viral encephalitis was reported from July through November 
2005 in Gorakhpur, Uttar Pradesh, India. It was the longest and most severe 
epidemic in 3 decades; 5,737 persons were affected in 7 districts of eastern Uttar 
Pradesh, and 1,344 persons died107. Japanese Encephalitis virus (JEV) is the most 
common cause of childhood viral encephalitis in the world, it causes an estimated 
50,000 cases and 10,000 deaths annually108,109. JEV is endemic in the Gorakhpur and 
Basti divisions of Eastern Uttar Pradesh. The geographic features of this region are 
conducive for the spread of JEV; an abundance of rice fields and a bowl-shaped 
landscape allow water to collect in pools. Heavy rains saturated the ground in 2005, 
which caused ideal breeding conditions for mosquitoes that transmit the virus from 
pigs to humans. 
Acute Encephalitas Syndrome (AES) occur regularly in several parts of 
India. Japanese Encephalitis virus (JEV) has been the major and consistent cause of 
these outbreaks in the Gorakhpur region of Uttar Pradesh state, accounting for  
10-15% of total AES cases annually110,111,112. In India, vaccinations against Japanese 
Encephalitis (JE) are administered in areas where the disease is hyperendemic, 
including Gorakhpur, and AES cases are regularly investigated to clarify the effects 
of vaccination. Currently, >2,000 patients with AES are admitted each year to Baba 
Raghav Das Medical College, Gorakhpur.  
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JEV is classified into 5 genotypes. Genotype III (GIII) is widely distributed 
in Asian countries, including Japan, South Korea, and the people’s Republic of 
China, Taiwan, Vietnam, the Philippines, India, Nepal, and Sri Lanka113. However, 
during the past decade, JEV GI has been introduced into South Korea, Thailand, and 
China and has replaced the GIII strains that have been circulating in Japan and 
Vietnam during the mid-1990114. Until 2007, all known JEV strains isolated in 
India115. 
Japanese Encephalitis is a seasonal disease, with most cases occurring in 
temperate areas from June to September. Further South, in subtropical areas, JEV 
transmission begins as early as March and extends until October. Transmission may 
occur all year in some tropical areas (e.g., Indonesia). Globally, more than 45,000 
cases are reported each year, although this is likely an under estimation of the true 
incidence of the disease120.  Local incidence rates range from 1-10 cases per 100,000 
persons but can reach more than 100 cases per 100,000 persons during outbreaks. 
The travel associated risk is overall relatively low (1 per 5,000–20,000 per week of 
travel), but the severity of natural infection and possible complications has been 
important factors that promote vaccination as a major preventive practice.  
Although most human infections are mild or asymptomatic, about 50% of 
patients who develop encephalitis suffer permanent neurologic defects and 30% of 
them  die  due  to  the  disease  116. In 1973, JE outbreak was first recorded in the 
districts of Burdwan and Bankura in West Bengal where 700 cases and 300 deaths 
were reported117-119. 
3.7.2 Epidemiology of Dengue virus 
Dengue is the most important arthropod-borne viral disease of public health 
significance. Compared with nine reporting countries in the 1950s, today the 
geographic distribution includes more than 100 countries worldwide. Many of these 
had not reported Dengue for 20 or more years and several have no known history of 
the disease. The World Health Organization estimates that more than 2.5 billion 
people are at risk of Dengue infection. First recognized in the 1950s, it has become a 
leading cause of child mortality in several Asian and South American countries121 
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Most people with Dengue recover without any ongoing problems. The mortality is 
1–5% without treatment68. 
In India, the first epidemic of clinical Dengue-like illness was recorded in 
Madras (now Chennai) in 1780 and the first virologically proved epidemic of 
Dengue fever (DF) occurred in Calcutta (now Kolkata) and Eastern Coast of India in 
1963-1964. During the last 50 years a large number of physicians have treated and 
described Dengue disease in India, but the scientific studies addressing various 
problems of Dengue disease have been carried out at limited number of centers122. 
Dengue has been present for centuries. The first recorded symptoms 
compatible with Dengue were noted in Chinese medical encylopedia in 992 AD, 
however originally published by the Chin Dynasty centuries earlier(265-420 AD) 
prior to being formally edited123.  The  disease  was  referred  to  as  water  poison  and  
was associated with flying insects124. Epidemics that resembled Dengue, with 
similar disease course and spread, occurred as early as 1635 and 1699 in the West 
Indies and Central America125. 
A major epidemic occurred in Philadelphia in 1780 and epidemics then 
became common in the USA into the early 20th century, the last outbreak occurring 
in 1945 in New Orleans125,126. The viral etiology and the transmission by mosquitoes 
were only finally determined in the 20th century. The origin of the primary mosquito 
vector, A. aegypti, is debated to be from either Africa or Asia127,125.  
Epidemics were spaced by 10-40 year intervals due to this shipping mode of 
transport126,123,128. Expansion of the disease heightened during World War II 
(WWII), when troops began to disperse inland and utilize modern transportation 
within and between countries,  thus epidemic Dengue became more far-reaching126. 
By the end of the war, transportation and rapid urbanization led to increased 
transmission of Dengue and hyperendemicity (multiple serotypes present) in most 
South  East  Asian  countries,  with  subsequent  emergence  of  the  severe  forms  of  
Dengue129,130. Global Dengue incidence has increased precipitously over the last five 
decades and severe Dengue cases have also expanded129,131,132.  
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Transmission of Dengue is now present in every World Health Organization 
(WHO) region of the world and more than 125 countries are known to be Dengue 
endemic. The true impact of Dengue globally is difficult to ascertain due to factors 
such as inadequate disease surveillance, misdiagnosis, and low levels of reporting. 
Currently available data likely grossly underestimates the social, economic, and 
disease burden. Estimates of the global incidence of Dengue infections per year have 
ranged between 50 million and 200 million; however, recent estimates using 
cartographic approaches suggest this number is closer to almost 400 million133. 
3.7.3 Epidemiology of West Nile virus 
The first reported case of West Nile virus came from the West Nile District 
of Uganda (1937)134. As of 2004, the virus has been detected throughout the entire 
United States. The peak incidence in North America falls between August and 
September. To date, WNV has been seen in Europe, Africa, parts of Asia, the 
Middle East, and North America135,136.  
WNV specific neutralizing antibodies have been detected in America, 
Borneo, China, Georgia, Iraq, Uganda, Kenya, Lebanon, Malaysia, Phillippines, 
Srilanka, Syria, Thailand, Tunisia, Turkey Belgian Congo and Sudan135,137. Recently 
the virus has been recognized in New York, America138. 
WNV is an emerging virus infection of the globe. Several outbreaks in 
different countries with various range of severity has been reported earlier136-140. The 
first known outbreak of WNV in the northern United states was observed during late 
August 1995 and due to the widespread virus activity, North Eastern USA is 
becoming endemic to WNV141,142,55. In human, clinically WNV appears as a mild, 
self limited, non-fatal, febrile illness rarely leading to encephalitis. However, 
myocarditis, a rare non-neurological complication143 and pancreatitis WNV 
infection144 and also have been reported.  
WNV has been isolated from sporadic cases of encephalitis and 
mosquitoes145. Work postulated a hypothesis of a zoogeographical interface of 
Japanese Encephalitis and West Nile virus. The hypothesis proposed the 
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intermingling distribution of JEV and WNV at the south Indian peninsular region. 
From the available data, it is evident that different viruses may predominate in 
different years since in south Arcot district of Tamil Nadu,146 observed a higher 
prevalence  of  neutralizing  antibodies  to  WNV than  JEV during  a  post  encephalitis  
outbreak survey in 1982, whereas in the same area, during 1989 and 1990 low 
prevalence of WNV. The increase in frequency of outbreaks, severe disease in 
humans and horses and high mortality rates in birds have emerged as the disturbing 
trends in the epidemiology of WN fever. 
Horses encounter the WNV infection like humans and experience 
encephalitis. Though the WNV encephalitis in horses is rare, a considerable 
mortality rate is reported in the case of encephalitis horses. WNV fever in horses has 
been reported in Egypt147, France148, Morocco149 Italy150 and in USA, infection in 
horses has not been documented in India. However in a recent survey, a significant 
rate of serological evidence against WNV has been noticed among horses in and 
around Pune city. Extensive studies of WNV infection in horses in India needs to be 
carried out. 
3.8 SIGNS AND SYMPTOMS 
3.8.1 Signs and symptoms of Japanese Encephalitis virus 
 Japanese Encephalitis has an incubation period of 5 to 15 days and the vast 
majority of infections are asymptomatic: only 1 in 250 infections develop into 
encephalitis62.  
 Most JE virus infections are mild (fever and headache) or without apparent 
symptoms, but approximately 1 in 250 infections results in severe disease 
characterized by rapid onset of high fever, headache, neck stiffness, disorientation, 
coma, seizures, spastic paralysis and death. The case-fatality rate can be as high as 
30% among those with disease symptoms. Of those who survive, 20–30% suffer 
permanent intellectual, behavioral or neurological problems such as paralysis, 
recurrent seizures or the inability to speak151. 
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Severe rigors mark the onset of this disease in humans. Fever, headache and 
malaise are other  non-specific symptoms of this disease which may last for a period 
of between 1 and 6 days. Signs which develop during the acute encephalitic stage 
include neck rigidity, cachexia, hemiparesis, convulsions and a raised body 
temperature between 38 and 41°C. Mental retardation developed from this disease 
usually leads to  coma151. 
 Mortality of this disease varies but is generally much higher in children. 
Transplacental spread has been noted. Life long neurological defects such as 
deafness, emotional ability and hemiparesis may occur in those who have had  
central nervous system involvement. In known cases some effects also include 
nausea, headache, and fever, vomiting and sometimes swelling of the testicles152. 
 Increased microglia activation following JEV infection has been found to 
influence the outcome of viral pathogenesis. Microglia are the resident immune cells 
of the central nervous system (CNS) and have a critical role in host defense against 
invading microorganisms. Activated microglia secrete cytokines, such as 
interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-Į), which can cause toxic 
effects in the brain. Additionally, other soluble factors such as neurotoxins, 
excitatory neurotransmitters, prostaglandin, reactive oxygen, and nitrogen species 
are secreted by activated microglia153. 
The severity of the disease in humans can be divided into 3 stages. 
¾ Prodromal stage-the onset of illness is usually acute and is heralded by 
fever, headache and malaise. The duration of this stage is usually 6 days. 
¾ Acute Encephalitis Stage-Fever is usually high, 38-41°C the prominent 
features are fever, neck rigidity convulsions (especially in infants) and 
altered sensorium progressing on many cases to coma. 
¾ Sequelae-More severe infection is marked by quick onset headache, high 
fever, neck stiffness, stupor, disorientation, spastic paralysis followed by 
gradual disturbances in speech change is mental status. (National vector 
borne disease control programme).  
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3.8.2 Signs and Symptoms of Dengue virus 
Dengue is a complex disease with a wide spectrum of clinical presentations, 
which often goes unrecognized or is misdiagnosed as other fever-causing tropical 
diseases154,155. Following the period of incubation, most patients experience a 
sudden onset of fever which can remain for 2–7 days and is often accompanied with 
symptoms such as myalgia, arthralgia, anorexia, sore throat, headaches, and a 
macular skin rash156,157. It is during this period that differentiating Dengue from 
other febrile diseases proves troublesome158.  
The majority of people experience a self-limiting clinical course, which does 
not  progress  to  the  severe  forms  of  Dengue,  Dengue  hemorrhagic  fever  (DHF),  or  
Dengue shock syndrome (DSS). Secondary Dengue infections or particularly 
virulent viral strains are two factors thought to be associated with increased risk of 
severity129,159. In severe cases, thrombocytopenia and increased vascular 
permeability can result in hemorrhagic and shock complications. Currently, neither a 
vaccine nor specific antiviral therapy exists160,161,162.  
 The characteristic symptoms of Dengue are sudden-onset fever, headache 
(typically located behind the eyes), muscle and joint pains, and a rash. The 
alternative name for Dengue, "break bone fever", comes from the associated muscle 
and joint pains. The course of infection is divided into three phases: febrile, critical, 
and recovery70. 
 The febrile phase involves high fever, often over 40°C (104°F), and is 
associated with generalized pain and a headache; this usually lasts two to seven 
days. Vomiting may also occur. A rash occurs in 50–80% of those with symptoms in 
the first or second day of symptoms as  flushed skin, or later in the course of illness 
(days 4-7), as a  measles like rash. Some petechial (small red spots that do not 
disappear when the skin is pressed, which are caused by broken  capillaries) can 
appear at this point, as may some mild bleeding from the  mucous  membranes of the 
mouth and nose. The fever itself is classically  biphasic in nature, breaking and then 
returning for one or two days, although there is wide variation in how often this 
pattern actually happens124,157. 
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 In some people, the disease proceeds to a critical phase around the time fever 
resolves160 and typically lasts one to two days. During this phase there may be 
significant fluid accumulation in the chest and  abdominal cavity due to increased  
capillary permeability and leakage. This leads to depletion of fluid  from the 
circulation and  decreased blood supply to vital organs. During this phase, organ 
dysfunction and severe  bleeding, typically from the gastro-intestinal tract, may 
occur68. Shock (Dengue shock syndrome) and haemorrhage (Dengue hemorrhagic 
fever)  occur  in  less  than  5%  of  all  cases  of  Dengue,  however  those  who  have  
previously been infected with other serotypes of Dengue virus (secondary infection) 
are at an increased risk. This critical phase, while rare, occurs relatively more 
commonly in children and young adults.  
The recovery phase occurs next, with resumption of the leaked fluid into the 
bloodstream108. This usually lasts two to three days. The improvement is often 
striking, but there may be severe itching and a slow heart rate. Another rash may 
occur with either a maculopapular or a vasculitic appearance, which is followed by 
peeling of the skin.  During this stage,  an overload state may occur,  if  it  affects the 
brain, it may cause a reduced level of consciousness or seizures. A feeling of fatigue 
may last for weeks in adults. 
3.8.3 Signs and symptoms of West Nile virus 
 The   incubation  period  for  WNV  the  amount  of  time  from  infection  to  
symptom onset is typically from between 2 and 15 days. Headache can be a 
prominent symptom of WNV fever, meningitis, encephalitis, meningoencephalitis 
and it may or may not be present in poliomyelitis-like syndrome thus headache is 
not a useful indicator of neuroinvasive disease54. 
 West Nile fever (WNF), which occurs in 20 percent of cases, is a febrile 
syndrome that causes  flu-like symptoms. Most characterizations of WNF generally 
describe it as a mild, acute syndrome lasting 3 to 6 days after symptom onset. 
Systematic follow-up studies of patients with WNF have not been done, so this 
information is largely anecdotal. In addition to a high fever, headache, chills,  
excessive sweating, weakness, fatigue, swollen lymph nodes, drowsiness, pain in the 
43 
 
joints and  flu-like symptoms74. Gastrointestinal symptoms which may occur include 
nausea,   vomiting,  loss  of  appetite,  and  diarrhea.  Less  than  one-third  of  patients  
develop a  rash. West Nile neuroinvasive disease (WNND), which occurs in less 
than 1 percent of cases, is when the virus infects the central nervous system resulting 
in  meningitis, encephalitis, meningoencephalitis or a  poliomyelitis-like syndrom54. 
 West Nile virus encephalitis (WNE) is the most common neuroinvasive 
manifestation of WNND. WNE presents with similar symptoms to other viral 
encephalitis with fever, headaches, and altered mental status. A prominent finding in 
WNE is  muscular weakness (30 to 50% of patients with encephalitis), often with  
lower motor neuron symptoms, flaccid paralysis, and hyporeflexia with no  sensory 
abnormalities . WNV is now the most common cause of epidemic viral encephalitis 
in the United States and it will likely remain an important cause of neurological 
disease for the foreseeable future. 
3.9 RECENT OUTBREAKS 
3.9.1 Recent Outbreak of Japanese Encephalitis in India 
 In India, the first human case was reported from North Arcot district of 
Tamil Nadu in 1955. Until 1973, the disease was confined to Southern parts of 
India, with low prevalence, subsequently the disease spread to various other parts of 
India. In 1978, suspected outbreaks of JE were reported from 18 states and 24 states 
and Union Territories have reported suspected JE cases till recent past163. 
 Japanese Encephalitis is severe disease and its epidemics are reported from 
many parts of India164.  Initial  cases  of  JEV were  reported  in  the  1950s  in  India165. 
The majority of the JEV cases during the year 1978, epidemic of JEV from eastern 
Uttar Pradesh (Gorakhpur and adjoining areas), which is the Terai area. Uttar 
Pradesh (a Northern State of India) and is surrounded by Urraranchal in the North 
East, Haryana and Himachal Pradesh in the North, Delhi and Rajasthan in the West, 
Madhya Pradesh in the South West, Chattisgarh in the South, Bihar in the South 
East and Nepal along the East164,166. 
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During 20th century extensive outbreaks of encephalitis was recognized in 
North  Eastern  India  with  7463  cases  reported.  In  the  North  region,  Uttar  Pradesh  
experienced its first epidemic in 1979 and the disease has continued there with 1716-
3894 cases per year. The outbreak of encephalitis have been reported from different 
parts of India, predominantly in the rural areas of Bihar, Uttar Pradesh, Assam, 
Manipur, Andhra Pradesh, Karnataka, Madhya Pradesh, Maharashtra, Tamil Nadu, 
Haryana,  Kerala,  West  Bengal,  Orissa  and  union  territories  of  Goa  and  
Pondicherry167. Occurrence of Epidemic of Japanese Encephalitis in Andhra 
Pradesh, during 1999, caused 178 deaths out of 873 peoples were affected168. In 
Northern states, the disease was reported between 1997 and 1981. 
3.9.2 Recent Outbreak of Dengue in India 
 Dengue infection is endemic in many parts of India. In India, the first 
epidemic of clinical Dengue-like illness was recorded in Madras (now Chennai) in 
1780. The first virologically proven epidemic of DF in India occurred in 1963-
1964169-171.  
 DHF was occurring in the adjoining countries but it was absent in India for 
unknown reasons as all the risk factors were present. The DHF started simmering in 
various parts of India since 1988172-174.  The  first  major  wide  spread  epidemics  of  
DHF/DSS occurred in India in 1996 involving areas around Delhi175 and 
Lucknow176 and then it spread to all over the country177. 
The very first report of existence of Dengue fevers in India was way back in 
1946178.  An initial  epidemic of Dengue fever was reported on the Eastern Coast of 
India171,18,179-187 it spread northwards and reached Delhi in 1967183 and Kanpur in 
1968184,185. Simultaneously it also involved the Southern part of the 
country186,187 and gradually the whole country was involved with wide spread 
epidemics followed by endemic/hyperendemic prevalence of all the four serotypes 
of DV. 
 DENV-2 was isolated during the epidemics of Dengue in urban and rural 
areas of Gujarat State during 1988 and 1989188. Outbreaks of Dengue occurred in 
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Rajasthan by DENV- 1 and DENV-3189, DENV-3190, Madhya Pradesh by DENV-
3191,  Gujarat  by  DENV-2188 and in Haryana by DENV-2192. DENV-2 was the 
predominant serotype circulating in Northern India, including Delhi, Lucknow and 
Gwalior175,176,193 while DENV-1 was isolated during the 1997 epidemic at Delhi194. 
The phylogenetic analysis by the Molecular Evolutionary Genetics Analysis 
programme suggests that the 1996 Delhi isolates of DENV-2 were genotype IV. The 
1967 isolate was similar to a 1957 isolate of DENV-2, from India, and was classified 
as genotype V. This study indicates that earlier DENV-2 strains of genotype V have 
been replaced by genotype IV195. 
3.9.3 Recent Outbreak of West Nile Virus in India 
 Though West Nile virus is reason for the encephalitis cases it can be said that 
in India the prevalence is very less compared to the outbreaks happened in U.S, 
Africa and European countries. The ratio of West Nile cases causing AES will be 2-
3% only. But when the epidemic outbreak happen the percentage of WNV causing 
AES might shoot up. Epidemiology of WN infection is not well known in India. 
Serological survey during JE epidemics and in areas endemic to JE shows that the 
virus is prevalent in India142.  
Fatal cases were seen in children196 unlike in the older age groups in the 
recent outbreaks in other countries. Despite the presence of mosquito vectors in 
abundance, and potentially neurovirulent strains of the virus, there have been no 
serious  epidemics  due  to  WNV  in  India  comparable  to  JE  outbreaks.  Reasons  for  
this situation are not clear, but presence of other flaviviruses in India could be an 
important factor for limiting the spread of WN or reducing its severity. 
An outbreak of acute encephalitis syndrome (AES) was reported in Kerala in 
India in May 2011. Serum neutralization assay result revealed that 32 of 42 
(76.19%) sera were positive for WNV neutralization antibodies197. 
3.10 LAB DIAGNOSIS 
1. Attempts to isolate virus from the blood of patients with flavivirus 
encephalitis are usually unsuccessful because viremia is transient and titres 
are low.  
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2. Virus is occasionally isolated from the cerebrospinal fluid of patients who do 
not yet have antibody.  
3. Viral ribonucleic acid occasionally may be detected in the cerebrospinal fluid 
by the reverse transcription polymerase chain reaction (PCR)198 for West 
Nile virus, real-time PCR has proved more useful.  
4. However, the accepted standard for diagnosing flavivirus encephalitis is the 
IgM capture enzyme-linked Immunosorbent assay (ELISA). This assay will 
often detect antibody on a single cerebrospinal fluid or serum sample.  
3.10.1 Culture 
Culturing the virus in susceptible cell cultures, such as rabbit kidney (RK-13) 
and African green monkey kidney (Vero) cells, or embryonating chicken eggs. 
Intracerebral inoculations of newborn mice are less likely to yield virus isolates from 
mammalian tissues than cell culture methods. More than one cell culture passage 
may  be  required  to  observe  cytopathic  effect  (CPE).  Virus  culture  is  the  gold  
standard, but it is rarely positive except in autopsy material, generally from the brain 
and other solid organs.  
3.10.2 Virus isolation 
Virus has rarely been cultured from serum, CSF and other tissues. 
Propagation of virus requires use of live cell cultures or suckling mice, and must be 
performed in a biosafety level 3 laboratory. Culture is insensitive compared with 
other techniques and is time-consuming, thus remains primarily a research tool.  
3.10.3 Complement fixation (CF) test 
CF assays capitalize on the ability of antigen-antibody complexes to trigger 
the complement cascade, and the sensitivity of antibody-coated erythrocytes to 
complement-mediated lysis199. If patient serum contains complement-fixing 
antibodies recognizing the antigen in question, exogenous (guinea pig) complement 
added to the system will be consumed, and thus unavailable to lyse the indicator 
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cells (antibody-coated erythrocytes) added to the system at a later time point. Thus, 
the absence of hemolysis (i.e., a visible red cell pellet topped by clear liquid) 
indicates the presence of antibodies to the antigen in question. Serial dilutions of a 
given specimen are tested, and the CF titre is defined as the highest dilution showing 
50% hemolysis. CF antibodies induced by flavivirus infections typically appear 
within 2 weeks after onset, and their levels begin to decrease about 2 months later, 
reaching baseline levels in 1–2 years200.  
Some flavivirus infected individuals do not produce complement-fixing 
antibodies; approximately 20% of patients infected with SLEV during an outbreak 
remained negative for CF antibodies for up to 8 weeks201. Other problems reflect the 
highly complex nature of the assay; it is labor intensive, requires highly trained 
personnel, and demands strict quality control of reagents. Although historically 
important, CF testing for WNV antibodies is rarely performed today; other assays 
discussed below have proven more sensitive and much less labor intensive. 
3.10.4 Haemagglutination inhibition (HAI) assay 
The HI assay capitalizes on the finding that flavivirus envelope proteins 
(haemagglutinins) bind to and agglutinate avian erythrocytes, and that antibodies 
from infected individuals block this agglutination118. Acetone-extracted serum is 
first absorbed with goose erythrocytes, followed by serial dilution; a defined amount 
of antigen prepared from suckling mouse brains is then added to each serum 
dilution. After an overnight incubation in the refrigerator, goose erythrocytes are 
added to each serum-antigen mixture; after an hour at room temperature, 
agglutination is scored. A thin mat of erythrocytes indicates agglutination, and thus 
the absence of serum antibodies capable of inhibiting agglutination; in contrast, a 
pellet of erythrocytes indicates agglutination inhibition, and thus the presence of 
antibodies capable of blocking the interaction between antigen and the goose 
erythrocytes. The HI titre is defined as the highest serum dilution completely 
inhibiting agglutination. 
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3.10.5 Plaque reduction neutralization test (PRNT) 
Although developed many years ago, the PRNT still serves as the gold 
standard for measuring specific antibodies, due to its exquisite specificity202. 
Multiple dilutions of patient serum are incubated with a live virus preparation 
containing a defined number of infective units. The serum-virus mixtures are then 
added to culture wells containing a confluent monolayer of Vero cells, which are 
susceptible to flavivirus infection. After culturing for a defined number of days, the 
number of plaques (visible areas of nonviable cells killed as a result of viral 
infection) is determined.  
Flavivirus specific antibodies in the serum bind to envelope proteins and 
neutralize the ability of the virus to infect Vero cells, as evidenced by a reduction in 
the number of plaques. The highest serum dilution reducing plaque formation by a 
given level (typically 80-90% reduction in plaque count) is defined as the endpoint 
titre. It is very useful in survey and confirmation of virus isolates. It aids in 
discriminating between the different flaviviruses because interpreting antibody 
levels is difficult, because flavivirus shows the cross reactivity with each other due 
to antigenic sharing among members of viridae.  PRNT is the most specific test  for 
the arthropod-borne flaviviruses, which can be used to help distinguish false-positive 
results in an IgM antibody- capture enzyme-linked immunosorbent assay or other 
assays (for example, indirect immunofluorescence and haemagglutination 
inhibition).  
3.10.6 Enzyme Linked Immunosorbent Assay (ELISA) 
The most efficient diagnostic method is detection of IgM antibody to WNV 
in serum collected within 8 to 14 days of illness onset or CSF collected within 8 
days of illness onset for IgM antibody-capture, enzyme-linked immunosorbent assay 
(MAC-ELISA), which is routinely used for the diagnosis of acute infection in 
humans203.  Most patients with WNND have detectable antibody in CSF and serum 
at the onset of neurological symptoms204. By the 8th day of illness, a large majority 
of infected persons will have detectable serum IgM antibody to flavivirus infection. 
In most cases it will be detectable for at least 1-2 months after illness onset, in some 
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cases it will reach undetectable levels prior to 1 month after illness onset or it will be 
detectable for 12 months or longer. By 3 weeks of post infection (often earlier), 
virtually all infected persons demonstrate long-lived serum IgG antibody to WNV. 
The most effective means of diagnosing flavivirus infection is antibody 
detection. Nearly all AES infected individuals are seropositive for flavivirus 
infection IgM within 14 days of the onset of symptoms. Essentially all patients with 
neurologic involvement have detectable IgM result for CSF reflects inthrathecal 
antibody synthesis, and is thus diagnostic of central nervous system infection.  
3.10.7 Reverse transcription Polymerase chain reaction (RT-PCR) 
PCR is a sensitive technique for identifying flavivirus genetic material in 
both serum and cerebrospinal fluid (CSF) as samples collected on days of onset 
below 5 days. RT-PCR protocol remains a useful tool for surveillance studies and 
evolutionary research owing to the possibility of obtaining epidemiological data 
through the sequence data. At present, an extensive number of Taq Man and SYBR-
Green RT-PCR commercial kits are available that are helpful for the standardization 
of robust and reliable real-time protocols, providing a good profile of sensitivity and 
specificity without needing extensive standardization.  
3.10.8 Indirect immunoflourescence assay (IFA) 
 Confirmation of flavivirus isolates is achieved by indirect fluorescent 
antibody staining of infected cultures. The solid phase for the WNV antibody IFA is 
a  glass  slide  well  coated  with  fixed  WNV-infected  cells;  diluted  serum  or  CSF  is  
added to the well, and after incubation and washing, fluorescein-labeled anti-human 
IgG or anti-human IgM is added. After another incubation and wash step, a cover 
slip is applied, and the slide is examined using a fluorescent microscope. A clearly 
visible cytoplasmic fluorescent pattern is interpreted as positive205,206.  
Slides for performing IFA are commercially available from Pan-Bio 
(Columbia, MD). Two technical issues regarding IFA performance are worth noting. 
First, the cell preparation bound to the glass slide well is typically a mixture of virus 
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infected and uninfected cells; thus, only some of the cells (typically 30%–50%) 
exhibit fluorescence when treated with an antibody-positive sample. Detection of 
fluorescence in all the cells is indicative of nonspecific staining, and thus cannot be 
interpreted as positive. Second, serum specimens for IgM determination should be 
diluted in sample buffer containing anti-human IgG, in order to remove the IgG in 
the sample. This treatment prevents false negative IgM results due to competition 
between IgG and IgM for available antigen binding sites; it also eliminates false 
positive IgM results caused by attachment of IgM rheumatoid factor to bound WNV 
specific IgG205,207. IFA offer some notable advantages over CF, HI and PRNT. The 
complex antigen preparation procedures of CF and HI are not required and in 
contrast to the PRNT, the risk of accidental infection of the person performing the 
assay is eliminated by fixation of infected cells.  
Since IFA can be performed in a single day, results are available much 
sooner compared to the other assays mentioned and also, the sample volume 
required for IFA is lower, making evaluation of CSF more practical205. The major 
advantage, however, is the ability to separately measure IgM and IgG antibodies by 
IFA, as opposed to measurement of total antibodies by the previously described 
methods. This information can be used to approximate the time since infection, 
particularly in situations such as seroprevalence studies, where a single specimen is 
tested and patient histories are not available.  
3.10.9 Micro sphere immunoassay (MIA) 
 All  screening  assays  for  WNV  antibodies  share  the  problem  of  cross  
reactivity with other flavivirus infections. Specific identification of the infecting 
flavivirus is achieved by concurrent testing for antibodies to flaviviruses found in a 
given geographic area. MIA may provide the means to simultaneously assess 
antibody levels to multiple flaviviruses rapidly at a reasonable cost.  
The most widely used MIA is the system developed by Luminex Corporation 
(Austin, TX). This system uses multiple polystyrene bead sets; each bead set 
contains distinctive proportions of red and orange fluorescent dyes that yield a 
signature fluorescent pattern when analyzed by a modified flow cytometer205. In its 
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most  basic  format  for  detecting  IgG to  different  antigens,  each  of  the  distinctively  
fluorescent bead sets can be covalently linked to a different antigen. These bead sets, 
each with a different antigen target, can then be mixed together in a single reaction 
well. Serum is added, and antibodies recognizing the antigens in the mixture bind to 
the antigens. Goat anti-human IgG conjugated to a fluorescent reagent 
(phycoerythrin) is then added as a reporter antibody, and binds to any captured IgG. 
The bead mixture is then simultaneously analyzed for the bead sets’ signature 
fluorescent patterns and the reporter antibody. The reporter fluorescence intensity is 
directly proportional to the amount of antigen-specific IgG bound to a given bead 
set. Thus, antibodies to multiple antigens can be measured in a single reaction 
well205.  MIA  offers  greater  sensitivity  than  ELISA  systems  due  to  (a)  a  broad  
dynamic range, (b) more surface area resulting in more available antigenic epitopes, 
and (c) the superior fluorescent characteristics of phycoerythrin. Less specimen 
volume is required for MIA because multiple assays are performed in a single 
reaction well, and the high precision of the assay eliminates the need for replicate 
testing. Finally, MIA is cost-effective, particularly from the standpoint of tests 
performed per microgram of antigen.  
3.10.10 Nucleic acid amplification tests (NAAT) 
 Nucleic acid amplification testing (NAAT) plays an important role in avian 
and mosquito surveillance programmes208. NAAT testing has been applied to 
diagnosis of human WNV disease with varying results. Early studies suggested a 
limited rule for NAAT based on the short duration of viraemia209. A more recent 
study performed during a large community outbreak of WNV infection in Canada 
found that 45% of plasma samples from patents with WNV infection had detectable 
virus210.  
 In  this  study,  the  primary  determinant  of  a  positive  PCR  was  duration  of  
symptoms. Plasma NAAT was positive among 56% of patients presenting within 
eight days of symptom onset compared with 4% of those presenting more than a 
week into clinical illness. The plasma viral load ranged from 50 copies to 1.4x105 
copies/ml  (mean 7.5  x103 copies/Ml),  with  no  association  between the  quantity  of  
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virus detected and the duration of symptoms and the presence of CNS involvement. 
Patients with WNND are much less likely to have detectable virus compared with 
those with WNF, perhaps reflecting the delayed onset of neurological symptoms. In 
the Canadian study cited above, 36% of patients with WNF had detectable virus in 
plasma compared with only 9.5% of those with WNND210.  
 PCR is a sensitive technique for identifying WNV in brain tissue, but is of 
limited use in detecting virus in spinal fluid. PCR is used in the diagnosis of WNV 
infections in humans, although it has limited usefulness because of the transient and 
low viremias. With PCR, WNV genetic material can be detected in CSF in up to 
50% of patients who present with acute West Nile meningoencephalitis.  
One study evaluating CSF PCR among patients with serologically confirmed 
WNND identified virus in 57% of samples using real-time PCR, and in 0% of 
specimens using conventional PCR211. The low yield of CSF PCR for diagnosis of 
WNV has been replicated by other investigators212.  While  NAAT  testing  is  not  
routinely recommended in immunocompetent hosts, molecular amplification tests 
may be diagnostically indicated for identification of WNV infection in 
immunocompromised patients, a population at high risk of central nervous system 
involvement and adverse outcomes.  
Case reports have documented positive NAAT in transplant patients and 
those with hematological malignancies. In this population viraemia may persist for a 
prolonged period of time, congruent with the delay in detectable neutralizing 
antibody213,214. Techniques that have been studied include real-time reverse 
transcription polymerase chain reaction (RT-PCR) and nucleic acid sequence-based 
amplification  (NASBA),  both  of  which  are  able  to  detect  as  few as  50  viral  RNA 
copies/ml215.  
Recently, the RT-PCR method for the detection of virus specific genome has 
been extensively used by several workers216,217,218. To increase the sensitivity and 
specificity certain modified assays viz., TaqMan assay216 and nucleic acid sequence 
based amplification method (NASBA)219 have been reported. The TaqMan assay has 
been successfully used for the detection of WNV in human CSF (cerebrospinal fluid) 
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that was found negative in conventional cell culture technique216. The other NASBA 
method  involves  the  use  of  three  enzymes  and  a  detection  system  of  
electrochemiluminescence (ECL). Alternately, molecular beacon probes have also 
been used as detection system219.  
3.11 PREVENTION OF FLAVIVIRUS INFECTION 
 Eight flaviviruses cause significant morbidity and mortality around the 
globe: Japanese Encephalitis (JE), Dengue 1, 2, 3, 4 and West Nile (WN). JEV and 
WN are zoonosis, with the consequence that vaccines are the only means of 
protecting humans. The successful YF 17D vaccine, introduced in 1937, produced 
dramatic reductions in epidemic activity220.  
For many years, only inactivated JE vaccines prepared from infected mouse 
brains were licensed for use by residents and travellers. Use of this vaccines resulted 
in an unacceptable level of adverse safety events and it production has been 
discontinued by major manufactures. Recently, JE vaccine landscape has changed. A 
safe and efficacious single dose, live attenuated vaccine produced in China has 
become available in many Asia countries. A new inactivated JE alum adjuvant 
vaccine is now licensed for use in Europe, Australia and the United States and a 
Yellow fever (YF-JE) chimeric vaccine candidate is nearing license in developed as 
well as developing countries220. The major outbreak of JE in Eastern UP during 
2005, Gol introduced JE vaccination with SA-14-14-2 vaccine in phased manner 
starting form 2006. 132 districts have already been brought under JE vaccination as 
part of Universal Immunization Programme (UIP). Out of 62 new districts proposed 
to be covered during 2012-13 and 2013-14, 16 districts have already been covered 
under JE vaccination during 2012-1362. 
There is no vaccine to prevent human infection by Dengue virus. Personal 
protection and the environment management of mosquitoes are important in 
preventing illness. Prevent access of mosquitoes to an infection person with a fever. 
Protect ourselves from mosquitoes bites at all times in Dengue areas. Use mosquito 
repellent Permethrin can be applied to clothing, shoes, camping gear and bed 
netting. Use 10% repellent to apply our skin. The mosquito that carry the Dengue 
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virus typically live in and around houses, breeding in standing water that can collect 
in such things as used automobile tires. Reduce the breeding habitat to lower 
mosquito populations. 
There  is  no  vaccine  to  prevent  human  infection  by  West  Nile  virus.  Apply  
repellent containing permethrin, picaridin, oil of lemon eucalyptus or DEET when 
mosquito are active to exposed skin, the more active ingredients a repellent contain 
the longer ;it can protect from mosquito bites. Repellents may irritate the eyes and 
mouth, so avoid applying repellent to the hands of children. Consider staying 
indoors at dawn, dusk and in the early evening, which are peak mosquito biting 
times. 
3.12 CONTROL MEASURES 
 Vector control measures have their limitations given the exophilic as well as 
exophagic tendencies of the proven vectors belonging to Cx.Vishnui group. Control 
measures should be implemented immediately. Vector control measures especially 
fogging the Malathion technical should be carried out immediately in the affected 
village, use of bed net, full sleeve clothes during evening hours should be promoted 
to prevent mosquito bites.  
 Outdoor resting habits and crepuscular nature, the vector control using 
indoor residual spray is technically not feasible. In addition due to the vast and 
enormous breeding habitats like perennial ponds, paddy fields and other water 
bodies  larval  control  using  ULV  fogging  (ultra  low  volume)  is  the  only  
recommended method of vector control. 
 Many flaviviruses are human pathogens of global importance, but no 
clinically approved antiviral therapy is currently available to manage these diseases. 
Both pharmaceutical industry and academia have invested considerable efforts over 
the past decade on finding the flavivirus antiviral using modern drug discovery. 
Various high-throughput compatible target-based and cell-based assays have been 
developed and implemented. 
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SCOPE AND PLAN 
 
4.1 SEROPREVALENCE STUDY 
 
Dengue, Japanese Encephalitis and West Nile encephalitis, are the common 
viral diseases associated with high morbidity and mortality. They are the leading 
cause of endemic/epidemic viral encephalitis in Asia, including India, Thailand, 
Vietnam, Singapore, the Philippines, Taiwan, China, Korea, and Japan221. It is also 
one of several mosquito-borne flaviviruses, in addition to four serotypes of Dengue 
virus (DENV-1 to -4), that have experienced emergence and reemergence 
throughout the world, especially in the tropical regions222,223. Sequential infection by 
multiple cocirculating flaviviruses in the affected population confounds 
serodiagnosis201 disease burden estimation224 and the impact on pathogenesis225. 
Flavivirus infections elicit protective antibody responses primarily against 
the envelope (E) glycoprotein201. The E protein contains three structural and 
functional domains. E domain I (EDI) is an eight-stranded ȕ-barrel; it contains two 
large insertion loops forming the elongate dimerization EDII and containing the 
highly conserved internal fusion peptide. EDIII has an immunoglobulin (Ig)-like 
structure and contains the primary receptor-binding motifs226,227. Murine monoclonal 
antibody (MAb) studies have demonstrated that EDI contains predominately type-
specific nonneutralizing (non-Nt) epitopes, EDII contains cross-reactive epitopes 
eliciting both Nt and non-Nt antibodies, and EDIII contains the majority of the type-
specific Nt epitopes228,229-234. 
There is not much data available on the seroprevalence of the flavivirus 
antibodies in the population of Tamil Nadu. A seroprevalence study will give us a 
clear picture about the exposure of the population to flavivirus. In the present study 
the serum and CSF samples collected from suspected cases of AES from Jan 2011 to 
December 2014 and based on the date of onset of illness the samples were tested for 
IgM antibody capture ELISA. The samples were collected at different age intervals 
0-12 yrs, 13-19 yrs, 20-35 yrs, 36-50 yrs and above 50 yrs. The seroprevalence study 
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give us a clear picture about the age wise, gender wise, month wise, season wise and 
district wise distribution of flavivirus causing AES. 
4.2 SCREENING OF AES PATIENTS FOR FLAVIVIRUS ETIOLOGY 
BY RT-PCR 
 The clinical diagnosis of flavivirus infections is not unambiguous due to 
unspecific symptoms varying from mild, febrile illness to viral hemorrhagic fever. 
Many of these flaviviruses have a common transmission vector and can co-circulate 
in the same area. All these factors make a precise identification of the pathogen 
difficult.  
 Today most diagnostic laboratories use serological assays for flavivirus 
testing. These tests are commonly based on the enzyme-linked immunosorbent assay 
(ELISA) and detect virus-specific IgM and IgG antibodies. Antibodies are 
undetectable prior to 5-7 days after onset of infection which hampers the usefulness 
of the serological methods. Molecular techniques, in contrast, can be used already in 
the acute phase and are known to be rapid, highly specific and sensitive.  
 Since the early 1990s, several group-specific and generic molecular assays 
for detection of flaviviruses have been developed as reviewed previously235-237. A 
number of attempts to detect several flaviviruses in a single reverse transcription-
polymerase chain reaction (RT-PCR) assay have been made238. These assays vary in 
the selected target region, assay format and detection method. The highly conserved 
NS3 and NS5 genes have been used predominantly for flavivirus testing, mainly as 
nested, hemi-nested RT-PCR or SYBR green real-time PCR, without using a probe 
for sequence verification.  
 The  scope  of  this  study  was  to  standardize  a  rapid,  sensitive  and  reliable  
TaqMan probe-based quantitative RT-PCR (qRT-PCR) assay for simultaneous 
detection of several flaviviruses, using the conserved NS5 gene region. The 
introduction of Locked-Nucleic Acid (LNA) bases in the probe increases robustness, 
specificity and sensitivity of the assay and has been shown to allow quantification of 
the viral load.  
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 In recent years, numerous molecular techniques utilizing a generic approach 
have been described for flavivirus diagnosis239-254. For identification of flaviviruses, 
molecular amplification methods targeting regions of highly conserved 
NS3 and NS5genes have been widely described, predominantly in the format of 
nested or heminested RT-PCR. In general, these techniques present lower sensitivity 
than specific flavivirus approaches when evaluated during EQA exercises for the 
molecular diagnosis of different flaviviruses. However, in some cases255 their 
performance is comparable256. The use of generic methods for the molecular 
diagnosis of flaviviruses is only advisable when post amplification identification 
techniques (e.g., sequencing and melting temperature) are performed afterwards. 
 Development of pan-flavivirus molecular diagnostic assays has intrinsic 
limitations owing to the genetic diversity among viruses of the genus. Although 
several attempts have been made to achieve universal detection of flaviviruses, the 
development of sensitive and specific pan-flavivirus assays remains an important 
task when addressing global health challenges. 
 Recently, some methods were developed for the detection and differentiation 
of two flaviviruses or a combination of flaviviruses and other arboviruses (i.e., 
Alphaviruses) sharing the same geographical distribution. These methods could be 
of interest to laboratories in endemic areas, but, again, a discrimination step must 
follow to reach an accurate diagnosis257-261. 
  In the present study the CSF samples which were collected at an acute onset 
of  illness  subjected  to  pan-flavi  conventional  RT-PCR.  The  CSF  samples  were  
transported to laboratory and stored at -20. The samples were initially processed for 
the conversion of cDNA and the pan-flavi conventional RT-PCR was performed. 
Further  the  pan-flavi  PCR  positive  samples  were  subjected  to  RT-PCR  for  JEV,  
DENV and WNV for the more sensitivity. 
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4.3 GENETIC CHARACTERIZATION, SEQUENCING AND 
PHYLOGENETIC ANALYSIS  
The genus flavivirus of the family viridae comprises over 70 viruses, many 
of which, such as the Japanese Encephalitis (JE) virus, Dengue (DEN) viruses, and 
West Nile virus are important human pathogens1,2. Dengue and its severe and 
sometimes fatal forms, Dengue hemorrhagic fever and Dengue shock syndrome, 
alone affect nearly 80 million people a year129,159. As demonstrated in recent 
outbreaks of meningitis by West Nile (WN) virus in Algeria and Romania, viruses 
of this group sometimes cause serious public health concern in unexpected 
locations262. In the present study, the pan-flavi PCR positive samples were subjected 
to RT-PCR for JEV, DENV and WNV for the more sensitivity. The genetic 
characterization of the above flaviviruses was performed to find out the genotypic 
characterization and mutational events were analyzed during the study period.  
The circulatory strains in Tamil Nadu will be come as Outcome of the study. 
The phylogenetic tree was constructed with the neighbor-joining method, with a 
bootstrap analysis of 1000 replicates, using MEGA software, version 2.1263. The 
Phylogram and slated cladogram will be constructed by pair-wise comparison of 
nucleotide sequences of the partial polypeptide genes which will be classified and all 
isolates into two different lineages. 
4.4 DEVELOPMENT AND STANDARDIZATION OF PAN-FLAVIVIRUS 
DETECTION SYSTEM (ELISA) USING PEPTIDE ANTIGEN TO 
ENABLE EARLY AND ECONOMICAL DETECTION OF 
FLAVIVIRUS INFECTION. 
 Several diagnostic systems are available for the detection of circulating 
flavivirus antibodies in patient serum264,265. However, no gold standard is available 
for immunological diagnosis. Since, PCR based diagnosis has become very 
common, it cannot be used in field conditions and requires trained manpower. A 
field based simple method to use pan-flavivirus detection system will be of great 
help specifically for low endemic areas to differentiate flavivirus infections from 
other viral infections266.  
59 
 
In the present study, the conserved amino acid sequence among JEV, DEN 
and WNV were identified and it was custom synthesized. The peptide having 
conserved amino acid sequence was used to generate polyclonal antibodies and these 
antibodies were used to detect flaviviruses.  
 Similarly the fusion peptide was given to challenge in vivo animal model 
system. The Swiss albino mice were selected as an animal model system. The Swiss 
albino mice were injected with fusion peptide as per the gold standard of 
immunization protocol. The mice will be sacrificed in the end of the treatment and 
liver, heart, kidney and lungs were observed for the pathological findings induced by 
pan-flavi fusion peptide. The histological findings will be exposed the mutagenicity 
and antigenicity of pan-flvi conserved peptide.  
Plan of the study 
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MATERIALS AND METHODS 
 
The  present  study  was  carried  out  in  the  department  of  Virology,  King  
Institute of Preventive Medicine & Research, Guindy, Chennai - 32 for the period 
from January-2011 to December-2014. 
Study sample: 
The cerebrospinal fluid (CSF) and serum samples received at King Institute 
of Preventive Medicine and Research (KIPM & R), Guindy, Chennai for the routine 
viral diagnosis of AES cases were obtained from various Government Hospitals as 
well as Private Hospitals in Tamil Nadu.  
Inclusion Criteria: 
Samples were collected from patients with Acute Encephalitis Syndrome 
(AES).  AES is  defined  as  a  person  of  any  age,  at  any  time of  year  with  the  acute  
onset  of  fever  and  a  change  in  mental  status  and/or  new onset  of  seizures  (sudden  
violent attack of an illness). 
Exclusion Criteria: 
The samples collected from the patient with other febrile illness. 
Serum sample 
The serum samples which are collected between 8 to 14 days from the date 
onset of illness were subjected to IgM capture ELISA. Blood samples collected from 
suspected cases, transported to lab in cold chain, serum separated and stored at  
-20°C till tested for ELISA. 
Cerebrospinal fluid (CSF) sample  
The CSF samples collected in acute stage of an infection (within 5 days from 
the date onset of illness) were included for the detection of flavivirus genome by 
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conventional RT-PCR and further processed for the detection of Japanese 
Encephalitis, Dengue and West Nile virus. So the conventional RT-PCR for the 
detection of these viruses was also standardized. The PCR positive samples were 
further used for the virus isolation, haemagglutination test and Immunofluorescence 
assay. The genetic characterization and phylogenetic analysis of PCR positive 
samples were also performed. 
5.1 SEROPREVALENCE  
The seroprevalence study was performed by detecting the presence of virus 
specific IgM antibody in serum and CSF samples collected from suspected AES 
cases. 
 JE IgM antibody capture ELISA in Serum & CSF 
The JEV specific IgM antibody in serum and CSF was detected by NIV kit 
approved by CDC and the following materials were provided in the kit.  
Materials 
x Anti-human IgM Coated test strips – Micro wells are coated with anti-human 
IgM antibodies(µ chain specific) and post coated to block binding of non 
specific proteins as well to stabilize the coated antibody.(12x8 wells).  
x JE Antigen-Ready to use. 
x Biotinylated flavivirus cross reactive monoclonal antibody: (Hx-B)- Ready 
to use.  
x Controls (Positive/Negative): Ready to use. 
x Avidin-HRP:  Ready  to  use  as  reagent.  The  solution  to  be  protected  from  
direct exposure to light. 
x Wash Buffer Concentrate - 10x concentrate of phosphate buffered saline pH 
(7.2-7.6) with Tween 20 and preservative (0.1% Proclin). Crystallization 
may occur at low temperatures. To correct, incubate at 37°C until clear. Mix 
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well. Dilute one part wash buffer concentrate with 9 parts of distilled water. 
Diluted buffer may be stored for 1 week at 2-25oC. 
x Sample Dilution Buffer - Ready to use. Stable at 2-8oC. 
x Tetramethylbenzidine (TMB) Substrate: Ready to use. The solution to be 
protected from direct exposure to light.  
x Stop Solution – Ready to use. 1 N- Sulphuric Acid. Stable at 2- 25°C.  
Methodology 
1. Dilute serum/plasma 1:100 or CSF 1:10 with sample dilution buffer. 
2. Mix properly with vortex mixture. 
3. Wash the coated/post coated wells thrice with wash buffer. 
4. Transfer 50µl of diluted samples to the appropriate wells. Add 50µl 
reconstituted positive control/negative control to respective wells. 
5. Keep the plates in a humidified box (A bread box with a soaked cotton/tissue 
paper) and incubate the plate at 37ºC for 1 hour. 
6. At the end of incubation, wash the plate five times with wash buffer. Tap the 
plate after last wash on a tissue paper. 
7. Add 50µl of JE antigen to each well. 
8. Repeat step no 5 & 6. 
9. Add 50µl of Hx-B to each well. 
10. Repeat step no 5 & 6. 
11. Add 50µl of Avidin-HRP to each well. Keep the plate in a humidified box (A 
bread  box  with  a  soaked  cotton)  and  incubate  the  plate  at  37ºC  for   
30 minutes. 
12. Repeat step no 6. 
13. Add 100µl of substrate (TMB/H2O2) to each well. 
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14. Incubate the plate in dark at room temperature. Wait for the development of 
colour, which normally develops in 10 ± 1 minutes. 
15. Stop the reaction with 100µl of 1N sulphuric acid (H2SO4). 
16. Measure the absorbance at 450nm within 10 minutes. 
Quality control 
Each kit is supplied with one Positive control and one Negative control. The 
controls are mainly used for validation of the test procedure and the interpretation of 
the results. 
Expected values are given below 
Positive: OD values  0.5. 
Negative: OD value   0.18. 
Interpretation of the results 
If OD value of sample tested exceeds OD of Negative control by a factor 5.0 
(Sample OD  Negative OD x 5.0), the sample should be considered as “Positive” 
for JEV infection. 
Dengue IgM antibody capture ELISA in Serum & CSF 
The  Dengue  specific  IgM  antibody  was  detected  by  NIV  kit  and  the  
following materials were provided in the kit. 
Materials 
x Anti-human IgM Coated test strips –Micro wells are coated with anti-human 
IgM antibodies (µ chain specific) and post coated to block binding of non 
specific proteins as well to stabilize the coated antibody.  
x Dengue Antigen (Recombinant) – Ready to use. 
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x Biotinylated  flavivirus cross reactive monoclonal antibody: (Hx-B) - Ready 
to use.  
x Controls (Positive/Negative): Ready to use. 
x Avidin-HRP:  Ready  to  use  as  reagent.  The  solution  to  be  protected  from  
direct exposure to light. 
x Wash Buffer Concentrate - 10x concentrate of phosphate buffered saline pH 
(7.2-7.6) with Tween 20 and preservative (0.1 % Proclin T). Crystallization 
may occur at low temperatures. To correct, incubate at 37°C until clear. Mix 
well. Dilute one part wash buffer concentrate with 9 parts of distilled water. 
Diluted buffer may be stored for 1 week at 2-25oC. 
x Sample Dilution Buffer - One bottles, 60 ml. Ready to use. Stable at 2-8oC 
until expiry. 
x Tetramethylbenzidine (TMB) Substrate : Twelve ml of TMB/H2O2 substrate 
is provided. Ready to use. The solution to be protected from direct exposure 
to light.  
x Stop Solution – 1 bottle, 12ml ready to use. 1 N- Sulphuric Acid. Stable at  
20 - 25°C till expiry.  
Methodology 
Ensure all reagents are equilibrated to room temperature (20-25°C) before 
commencing assay.   
1. Dilute serum/plasma 1:100 or CSF 1:10 with sample dilution buffer. 
2. Mix properly with vortex mixture. 
3. Wash the coated/post coated wells thrice with wash buffer. 
4. Transfer 50µl of diluted samples to the appropriate wells. Add 50µl 
reconstituted positive control/negative control to respective wells. 
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5. Keep the plates in a humidified box (A bread box with a soaked cotton/tissue 
paper) and incubate the plate at 37ºC for 1 hour. 
6. At the end of incubation, wash the plate five times with wash buffer. Tap the 
plate after last wash on a tissue paper. 
7. Add 50µl of antigen to each well. 
8. Repeat step no 5 & 6. 
9. Add 50µl of Hx-B to each well. 
10. Repeat step no 5 & 6. 
11. Add 50µl of Avidin-HRP to each well. Keep the plate in a humidified box (A 
bread box with soaked cotton) and incubate the plate at 37 ºC for 30 minutes. 
12. Repeat step no 6. 
13. Add 100µl of substrate (TMB/H2O2) to each well. 
14. Incubate the plate in dark at room temperature. Wait for the development of 
colour, which normaly develops in 10 ± 1 minutes. 
15. Stop the reaction with 100µl of 1N sulphuric acid (H2SO4). 
16. Measure the absorbance at 450nm within 10 minutes. 
Quality control  
Each kit is supplied with one Positive control and one Negative control. The 
controls are mainly used for validation of the test procedure and the interpretation of 
the results. 
Expected values are given below 
Positive: OD values   0.5 
Negative: OD value   0.18 
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Interpretation of the results 
If OD value of sample tested exceeds OD of Negative control by a factor 3.0 
(Sample OD  Negative OD x 3.0), the sample should be considered as “Positive”. 
West Nile IgM antibody capture ELISA in Serum and CSF 
The West Nile specific IgM antibody was detected by Panbio kit (Inverness 
Medical Innovations Australia Pty Ltd, Australia) approved by CDC,Atlanta and the 
following materials were provided in the kit. 
Materials 
x Anti-human IgM Coated  Microwells  -  (Assay  Plate) Microwells are coated 
with polyclonal sheep anti-human IgM antibodies (12x8 wells). Ready for 
use.  
x West Nile Virus Antigen (NY99 strain) - Ready for use. Inactivated WNV 
antigen in phosphate buffered saline (pH 7.0-7.4) with glycerol, 
preservatives (0.1% Proclin™, 0.05% gentamycin sulphate) and protein 
stabilizers. Stable at 2-8ºC until expiry.  
x Wash Buffer Concentrate - 20x concentrate of phosphate buffered saline (pH 
7.2-7.6) with Tween 20 and preservative (0.1% Proclin™). Crystallization 
may occur at low temperatures. To correct, incubate at 37ºC until clear. Mix 
well. Dilute one part wash buffer concentrate with 19 parts of distilled water. 
Diluted buffer may be stored for one week at room temperature (20-25ºC).  
x Sample Diluent - Ready for use. Tris buffered saline (pH 7.2-7.6) with 
preservatives (0.1% Proclin™) and additives. Stable at 2-8ºC until expiry.  
x HRP Conjugated Monoclonal Antibody Tracer - Ready for use. Horseradish 
peroxidase conjugated mouse monoclonal antibody (to flavivirus E-
glycoprotein) tracer with preservative (0.1% Proclin™) and protein 
stabilizers. Stable at 2-8ºC until expiry.  
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x Tetramethylbenzidine TMB - Ready for use. A mixture of 3,3’,5,5'-
tetramethylbenzidine and hydrogen peroxide in a citric-acid citrate buffer 
(pH 3.5-3.8). Stable at 2-8ºC until expiry.  
x Positive Control - 400ȝL human serum (contains 0.1% sodium azide and 
0.005% gentamycin sulphate). Stable at 2-8ºC until expiry.  
x Cut-off Calibrator - 600ȝL human serum (contains 0.1% sodium azide and 
0.005% gentamycin sulphate). Stable at 2-8ºC until expiry.  
x Negative Control - 400ȝL human serum (contains 0.1% sodium azide and 
0.005% gentamycin sulphate). Stable at 2-8ºC until expiry.  
x Stop Solution - Ready to use. 1M Phosphoric acid. Stable at room 
temperature (20-25ºC) until expiry.  
Methodology 
Ensure all reagents are equilibrated to room temperature (20-25ºC) before 
commencing assay. Performing the assay outside the time and temperature ranges 
provided may produce invalid results. Assays not falling within the established time 
and temperature ranges must be repeated. 
1. Dilute  controls  (negative,  positive  and  calibrator)  and  the  serum  sample  
1:100 with sample diluent and the CSF sample 1:10. 
2. Calculate the number of wells accordingly mix equal volume of West Nile 
antigen and Mab tracer in a sterile vial. Mix it properly using vortex mixer 
and incubate at room temperature for 1 hour.  
3. Within 10 minutes after mixing the MAb Tracer and antigen, pipette 100ȝL 
diluted sample and controls into the respective microwells of the assay plate.  
4. Cover plate and incubate for 60 minutes at 37 ºC ± 1ºC. 
5. Wash six times with diluted wash buffer.  
6. Cover the plate and incubate for 1 hour at37°C ± 1°C.  
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7. Wash six times with diluted wash buffer.  
8. Mix the antigen-MAb tracer solution before transfer. Pipette 100ȝl of 
antigen-MAb complexes to the appropriate wells of the assay plate.  
9. Cover plate and incubate for 1 hour at 37°C ± 1°C.  
10. Wash six times with diluted Wash Buffer. 
11. Pipette 100ȝl TMB into each well.  
12. Incubate for 10 minutes at room temperature (20 - 25ºC), timing from the 
first addition. A blue color will develop.  
13. Pipette 100ȝl of stop solution into all wells in the same sequence and timing 
as the TMB addition. Mix well. The blue color will change to yellow.  
14. Within  30  minutes  read  the  absorbance  of  each  well  at  a  wavelength  of  
450nm with a reference filter of 600-650nm. 
Calculation 
(1) Calculate the average absorbance of the triplicates of the cut-off calibrator. 
This is the cut-off value.  
(2) An index value can be calculated by dividing the sample absorbance by the 
cut-off value (calculated in step 1 above).  
Sample Absorbance  
Index Value = ------------------------- 
    Cut-off Value 
Alternatively 
 
(3) Panbio Units can be calculated by multiplying the index value (calculated in 
step 2 above) by 10. 
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Interpretation of the results 
If the panbio units of sample tested exceeds 11, the sample should be 
consider as positive for West Nile virus infection. 
5.2 Pan-flavi PCR  
The conventional PCR was performed in the CSF sample collected at acute 
onset  of  illness  (sample  collected  within  5  days  from the  date  of  onset  of  illness).  
The samples were collected and stored at -20°C till the process. RNA extraction 
from CSF samples were done using Qiagen kit. cDNA was synthesized using 
random primers and PCR was performed first with flavivirus specific primer and the 
positives were then tested with primers specific for specific virus. 
Materials for RNA extraction 
The QIAamp Viral RNA kit (QIAGEN) was used for the extraction of RNA 
from CSF samples and the following materials were provided in the kit 
x QIAamp mini spin columns 
x Collection tubes (2mL) 
x Viral lysis Buffer (AVL) 
x Wash Buffer AW1 (concentrate) 
x Wash Buffer AW2 (concentrate) 
x Elution Buffer (AVE) 
x Carrier RNA (poly A) 
x 99% Ethanol 
x 1.5mL micro centrifuge tubes 
x Micro centrifuge 
Miscellaneous – Pipette (1000ȝl, 100ȝl), disposable sterile tips, tissue papers 
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Methodology 
 a) Preparation of viral lysis buffer 
 
 Add  310µl  of  AVE  buffer  to  one  tube  of  lyophilized  carrier  RNA  
(310µg) and dissolve thoroughly. Aliquot 28µl (for 5 reactions) and 
store at -20°C. 
 Aliquot 560µl of AVL buffer and store at room temperature. 
 Always  prepare  AVL buffer  freshly,  add  5.6µl  of  AVE+ Carrier  RNA 
(kept at -20°C) to 560µl of AVL buffer (kept at room temperature). 
b) Preparation of AW1 buffer  
Buffer AW1 is supplied as a concentrate. Before using for the first time, add 
the appropriate amount of ethanol as indicated on the bottle. Store the buffer 
at room temperature.  
c) Preparation of AW2 buffer  
Buffer AW2 is supplied as a concentrate. Before using for the first time, 
add the appropriate amount of ethanol as indicated on the bottle. Store the 
buffer at room temperature. 
Note: All centrifugations steps are at room temperature. 
 Buffer AVL + carrier RNA stored at 2-8oC forms a precipitate which 
must be re dissolved by warming at 80°C) for not more than 5 
minutes. Cool to room temperature before use. 
 Do  not  warm  Buffer  AVL  +  carrier  RNA  solution  for  more  than  6  
times, hence preferably aliquot in small quantities. 
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RNA extraction procedure:  
 Pipette 560µl of prepared Buffer AVL containing carrier RNA into a 1.5ml 
micro centrifuge tube. (If the sample volume is larger than 140µl then 
increase the amount of buffer AVL or carrier RNA proportionally, e.g. 280µl 
sample will require 1120µl of buffer AVL or carrier RNA). 
 Add 140µl of sample. Vortex - spin for 15 sec. 
 Incubate at room temperature for 10 minutes 
 Briefly centrifuge the 1.5ml micro centrifuge tube to remove drops from the 
inside of the lid. 
 Add 560µl of ethanol (96-100%) to the sample and mix by pulse overtaxing 
for 15 sec. briefly centrifuge to remove drops from inside the lid. 
 Carefully apply 630µl of solution from step 5 to column. Centrifuge at 8000 
rpm for 1 min. Place column into a clean 2ml collection tube and discard the 
tube containing the filtrate. 
 Repeat step 6. 
 Add 500µl of Buffer AW1.Cetrifuge at 8000 rpm for 1 minute. Place 
column into a clean 2ml collection tube and discard the tube containing the 
filtrate. 
 Add 500µl of Buffer AW2.Centrifuge at full speed (14000rpm) for 4 minutes. 
 Place the column in a clean 2ml collection tube and discard the old 
collection tube with the filtrate. Centrifuge at full speed for 1 minute. 
 Place the column in a clean 1.5ml micro centrifuge tube. Add 60µl of Buffer 
AVE, incubate at room temperature for 1 minute. Centrifuge at 8000rpm for 
1 minute. 
 In case of storage, store RNA at -20°C or -70°C till further use. 
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Synthesis of cDNA 
 
The total viral RNA was reverse transcribed to complementary DNA using 
reverse transcriptase core kit developed by Eurogentec, Belgium and the following 
materials were provided in the kit. 
Materials  
x 10x reaction buffer (black cap): one bottle of RT reaction buffer KCl and 
Tris-HCl 
x EuroScript reverse transcriptase (white cap): One tube of Moloney Murine 
leukemia virus reverse transcriptase, 3750U at 50 U/µl. 
x RNase Inhibitor (purple cap): One tube of RNase inhibitor 2400U/ µl. 
x 2.5mM dent mix(green cap): One tube of dATP,dCTP,dGTP and dTTP in 
autoclaved,deionized water titrated with NaOH to pH 7.0. 
x 25mM MgCl2 (orange cap): One tube of 25mM MgCl2 
x Oligo d(T)15VN (yellow cap): One tube containing 50µM 
oligodeoxynucleotides of sequence d(T)15VN in 10nm Tris-HCl, pH 8.3. 
x Random Nonomers (pink cap): One tube containing 50mM short 
oligonucleotides of random sequence (d(N)9) in 10mM Tris-HCl, pH 8.3. 
x RNase free water(plain cap): One tube of DEPC water.  
 
Template 
 
The RNA extracted from the CSF samples of suspected cases and stored at   
-20°C. The prototype virus (JEV, DENV and WNV) obtained from NIV raised in 
Vero cell line and the RNA was extracted from the cell culture fluids. It was used as 
a positive control for each run of the PCR. 
 
Methodology 
 
Thaw all required reagents necessary for the RT step completely and put 
them on ice, except for the EuroScript, which should be kept in the freezer until 
require for use. Mix all reagents well by inversion and spin them down prior to 
pipetting. 
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Preparation of RT reaction mix (10µl for 1x) 
 
10x reaction buffer  -  2µl 
25 mM MgCl2   - 4µl 
2.5mM dNTP    - 4µl  
Random nonamer   - 1µl   
RNAse Inhibitor    - 0.4µl 
EuroScript RT   - 0.5µl  
RNase free water   - 6.1µl 
Template    - 2µl 
Total mix   - 20µl 
 
x Add all components together except for the template. Mix thoroughly by 
inversion. Spin down. 
x Add the template to individual reactions, gently mix by inversion and spin 
down. 
x A negative control containing no RNA template should always be included. 
x Program the thermo cycler with the following cyclic conditions 
 
Initial step    - 10 min 25°C 
 
Reverse Transcriptase step  - 30 min 48°C 
 
Inactivation of RT enzyme  - 5 min 95°C 
 
  
Figure 5.1: Cyclic condition for cDNA synthesis 
 
 
x The synthesized cDNA was stored at -20°C. 
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Materials for Pan-flavi PCR 
 
x cDNA synthesized from CSF samples 
x Positive control (Prototype virus raised in Vero cell line) 
x Primers sequence given in Table 5.1 
x Phusion High-Fidelity PCR Master Mix with HF Buffer 
x Nuclease free water 
x 0.2ml PCR tubes 
x Pipettes (l-10µl, 20-200µl, 1000µl) 
x gloves (powder free)  
x 1.5ml microtubes (nuclease free) 
x 0.6ml microtubes (nuclease free) 
x Filter barrier tips (p10 to p1000) 
x Thermal Cycler  
x Gel casting tray 
x Electrophoresis chamber with power supply 
x UV Transilluminator 
x 2% Agarose gel in 0.5% TBE 
x Ethidium Bromide 
x Gel loading buffer (50% glycerol, 25% Bromophenol blue and >25% Xylene 
Xyanole) 
x Molecular weight marker (100-1000 DNA ladder) 
Methodology for Pan-flavi PCR 
One Step PCR Reaction Mix 
25Pl reaction volume containing 12.5Pl of Phusion high-fidelity PCR master 
mix with HF buffer, 1Pl of forward and reverse primers, 7.5Pl of Nuclease free 
water and 3Pl of cDNA was taken into the reaction mix. 
75 
 
Reaction Cycle 
The thermal cycler was programmed with the cyclic condition illustrated in 
the figure 5.2. 
Figure 5.2: Cyclic condition for pan-flavi PCR 
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Table 5.1: Primer sequence for Pan-flavi, JE, Dengue and WNV PCR 
Primer Name Sequence (5'- 3')  Base pair 
Pan-flavi PCR 
FU1(F)250 TACAACATGATGGGAAAGAGAGAGAA 655 
cFD4(R) ACCACACAATCATCTCCGCT 
JEP-1(F)267 CACAACGAGAAGCGAGCTGATAGTA 
241 
JEP-2(R) CCCCAACTTGCGCTGAATAATTCCC 
Pan Dengue PCR268 
(MD1-D2) TCAATATGCTGAAACGCGAGAGAAACCG 511 
D2 TTGCACCAACAGTCAATGTCTTCAGGTTCC 
Dengue 1 
(MD1/MTS1-) CCCGTAACACTTTGATCGCT 208 
Dengue 2 (MD1-
TS2) CGCCACAAGGGCCATGAACAG 119 
Dengue 3(MD1-TS3) TAACATCATCATGAGACAGAGC 288 
Dengue 4 
(MD1/MTS4-5) TTCTCCCGTTCAGGATGTTC 260 
West Nile (F)269 GCCGGGCTGTCAATATGCTAAAA 396 
West Nile (R) GCACTGGTCAAGGTCCCTAGTTC  
 
Methodology for JE PCR 
One Step PCR Reaction Mix 
25Pl reaction volume containing 12.5Pl of Phusion high-fidelity PCR master 
mix with HF buffer, 1Pl of forward and reverse primers, 7.5Pl of Nuclease free 
water and 3Pl of cDNA was taken into the reaction mix. 
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Reaction Cycle 
The thermal cycler was programmed with the cyclic condition illustrated in 
the figure 5.3. 
Figure 5.3: Cyclic condition for JE PCR 
 
Methodology for Dengue PCR 
One Step PCR Reaction Mix 
25Pl reaction volume containing 12.5Pl of Phusion high-fidelity PCR master 
mix with HF buffer, 1Pl of forward and reverse primers, 7.5Pl of Nuclease free 
water and 3Pl of cDNA was taken into the reaction mix. 
Reaction Cycle 
The thermal cycler was programmed with the cyclic condition illustrated in 
the figure 5.4. 
Figure 5.4: Cyclic condition for Dengue PCR 
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For Dengue genotyping  
25Pl reaction volume containing 12.5Pl of Phusion high-fidelity PCR master 
mix with HF buffer, 1Pl of forward primer(common for all genotype) and 1Pl of 
reverse primer(specific for each genotype illustrated in Table 5.1) ,7.5Pl of Nuclease 
free water and 3Pl of cDNA was taken into the reaction mix. The cyclic condition 
was same as shown in figure 5.4. 
Methodology for West Nile PCR  
One Step PCR Reaction Mix 
25Pl reaction volume containing 12.5Pl of Phusion high-fidelity PCR master 
mix with HF buffer, 1Pl of forward and reverse primers, 7.5Pl of Nuclease free 
water and 3Pl of cDNA was taken into the reaction mix. 
Reaction Cycle 
The thermal cycler was programmed with the cyclic condition illustrated in 
the figure 5.5. 
Figure 5.5: Cyclic condition for WNV PCR 
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Product Analysis by Agarose Gel Electrophoresis 
x 2g of Agarose was dissolved in 100ml 0.5XTBE buffer and melted using 
hotplate. Once completely melted, 2µl of Ethidium bromide was added and 
mixed completely. 
x The melted agarose was poured on to the gel plate with comb and allowed 
for solidification for at least 1 hour. 
x After solidification the gel plate was kept in electrophoresis tank containing 
0.5X TBE buffer and comb was removed. 
x 8µl of PCR product was mixed with 2µl of gel loading dye and loaded into 
gel. The electrophoresis apparatus was run for 40 minutes. 
x Once electrophoresis completed, the gel was visualized under UV 
transilluminator and the image captured using gel documentation system. 
5.3 Genetic characterization of the positive samples 
RT-PCR using flavivirus primer was performed and the PCR product was 
sequenced according to the standard protocols. Amplicons were purified using 
QIAquick PCR purification kit (Qaigen) and subjected to cycle sequencing using 
ABI Prism Big Dye terminator V3.1 cycle sequencing kit. Post-cycle sequencing 
purification was done using DyeEx2.0 spin kit (Qiagen). Sequencing was performed 
on ABI Prism 310 and sequence alignment and phylogenetic analyses will be done 
using Mega version 6. 
Virus Isolation 
 
The virus isolation was performed for the PCR positive CSF samples in Vero 
cell line (African green monkey kidney). The cell line was obtained from National 
Centre for Cell Science (NCCS), Pune and maintained in tissue culture lab facility 
available in the department of virology, KIPM & R. The following materials were 
used for the preparation of media and tissue culture work. 
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Materials for media preparation and tissue culture work 
 
Tissue Culture flasks 25cm2 
5ml, 10ml, pipettes 
Minimum Essential Medium (MEM)  
Trypsin Phosphate buffered saline Versene Glucose (TPVG) 
Beaker with 1% hypo chloride solution 
Gloves 
Spirit  
Cotton 
Label pad, Marker  
Preparation of ingredients for Media 
Penicillin and Streptomycin: (Conc.100IU of penicillin and 100Pg of 
streptomycin) 
  1 X 106 units of crystalline penicillin and 1g of streptomycin were dissolved 
in 100ml of PBS. 1ml of this stock was added to 100ml of medium to give a final 
concentration of 100IU penicillin and 100Pg of streptomycin. Stored at -20oC. 
Kanamycin Acid Sulphate (Conc:20Pg/ml) 
  1g of kanamycin was dissolved in 50ml millipore double distilled water and 
mixed well to a final concentration of 20Pg/ml and stored at -20oC 
Fungizone : Amphotericin B – 50mg (Conc:20Pg/ml) 
 50mg of amphotericin B was dissolved in 5ml of sterile Millipore distilled 
water and 1ml of this stock was diluted to 100ml of sterile Millipore distilled water 
to a final concentration of 20Pg/ml and stored at -20qC.  
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3% L-Glutamine  
 6g of L-Glutamine was dissolved 200ml of sterile millipore distilled water and 
mix well. It was filtered through 0.22 micron membrane and distributed as 5ml in 
polypropylene vial and stored at -20qC.  
7.5% Sodium-bi-carbonate solution  
 22Pg of Sodium Bicarbonate was dissolved in 200ml of sterile millipore 
distilled water and filtered through Whatmann filter paper No.4 and autoclaved. It 
was stored at +4qC. 
Fetal Bovine Serum 
 Fetal bovine serum was thawed at room temperature and inactivated at 56qC in 
water  bath  for  ½  hour  and  cooled  at  room  temperature.  If  floating  particles  were  
observed it was filter through Seitz filter and stored at -20qC.  
Trypsin, PBS, Versene, Glucose solution : (TPVG) 
  Phosphate Buffered Saline 
NaCl A.R  - 8g 
KCl A.R  - 0.2g 
Na2HPO4 A.R  - 2.88g 
KH2PO4 A.R  - 0.2g 
pH    - 7.4 
All the above ingredients were dissolved in 1000ml of sterile distilled water 
and filtered through whatmann filter paper No.4 and autoclaved. 
2% Trypsin 
 2g of trypsin was dissolved in 100ml sterile millipore distilled water stirred for 
30 minutes with help of magnetic stirrer. The solution was filtered through 
membrane filter and stored at -20qC. 
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0.2% EDTA (Versene)  
  200mg of EDTA was dissolved in 100ml of sterile millipore distilled water 
and autoclaved. 
10% Glucose A.R.-10ml 
  1g of glucose was dissolved in 10ml of sterile millipore distilled water and 
filter through whatmann filter paper and autoclaved. 
 TPVG    - 1000ml   
  PBS   - 840ml 
  2% Trypsin  - 50ml 
  0.2% EDTA -  100ml 
  10% Glucose  - 5ml 
 P&S  - 5ml 
 All the ingredients were mixed and pH was adjusted to 7.4 and stored at -20qC.  
0.4% Phenol Red  
 0.04g of Phenol red was dissolved in 10ml of double distilled water and 
autoclaved.  
Trypan blue for cell counting (0.1%)  
 0.1g of Trypan blue was dissolved in 100ml of phosphate buffered saline, 
filtered through whatmann filter paper No.4 and store at 4oC.  
Methods for the media preparation 
The following table illustrates the composition of media and its preparation. 
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Table 5.2: MEM Preparation Procedure 
Ingredients 
10% Growth 
Media 
2% Maintenance 
Media 
MEM 861ml 941ml 
P&S (Penicillin & Streptomycin) 1ml 1ml 
Phenol red (0.4%) 1ml 1ml 
Kanamycin 1ml 1ml 
Fungizone 1ml 1ml 
3% L-Glutamine 10ml 10ml 
Fetal Bovine Serum 100ml 20ml 
2.2g Sodium bicarbonate 20ml 20ml 
Hepes buffer (IM) 5ml 5ml 
Total volume  1000ml 1000ml 
 
All the ingredients were mixed well by shaking gently and pH was checked 
and adjusted to 7.2 to 7.4. 
Maintenance of Cell Lines 
¾ Tissue culture bottles that showed confluent monolayer were selected by 
observing them under an inverted microscope.  
¾ Growth medium was removed from the bottle, washed with PBS/MEM 
without FCS and 5ml of TPVG (for 25cm2 ) was added dispersing evenly 
on the monolayer and left in contact with the cells for 2-3 minutes.  
¾ TPVG was removed and the bottle was incubated at 37qC, until all the cells 
were detached from the surface.  
¾ The cells were re-suspended in 5ml of growth media. The suspension was 
aspirated few times to break cell clumps.  
¾ The cell concentration was determined by counting the cells in 
haemocytometer.  
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Cell Counting 
¾ A 0.2ml of the cell suspension was diluted in 0.2ml of trypan blue (0.1% 
trypan blue).  
¾ It was mixed well with pipette and sufficient volume was aspirated to fill 
haemocytometer immediately.  
¾ The viable cells (nonviable cells are stained blue and viable cells remain 
unstained) were counted in each of the four corners of both chambers, 
omitting cells lying on the top and to the left. 
¾ If cell clumping was observed, it was discarded and original cell 
suspension was re-suspended. 
¾ The total number of cells in the suspension was calculated using the 
following formula. 
Average cell count x dilution factor x 104 = - lakhs/ml 
Or C1 = t x tb x ¼ x 104  
 where   C1 = Initial cell concentration per ml 
  t  = total viable cell count of 4 squares 
  tb =  Correction to the trypan blue dilution 
  1/4  = correction to give mean cells per corner square. 
  104  = conversion factor for counting chamber. 
¾ Based on the cell count, sterile flasks/tubes were seeded and incubated at 
37qC.  
¾ Cell lines were not passaged beyond 15 times. 
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For preparation of 25cm2 flask 
Growth  medium  was  dispensed  to  fresh  sterile  cell  culture  flasks  to  be  
seeded with cells (9ml/25cm2 flask). The cell suspension was seeded to the TC 
flasks  at  1.0  x  105 cells/flask. Each flask was labeled with cell name, passage 
number and date of passage and incubated in 5% CO2 environment for 48 hours. 
Virus inoculation 
x 48 hours old healthy, confluent, vero cell line grown in 25 cm2 tissue 
Culture flasks were choosen.  
x Media was removed from flask with sterile pipette. 
x Add 50µl of  CSF  sample  to  25cm2 flask using sterile pipettes. Inoculum 
was allowed to adsorb for 30 minutes at 37C. 
x Add 10ml of maintenance media contain 2% fetal bovine serum to each 
flask and incubate at 37°C. 
x Flasks were observed daily for cytopathic effect (CPE).  
Haemagglutination test (HA) 
The  JE,  Dengue  and  West  Nile  viruses  are  able  to  agglutinate  the  RBC  of  
goose and it is pH dependent. So it is necessary to titrate the antigen in different pH 
solution. The optimum pH for haemagglutination was determined. 
 Materials 
x Virus adjusting diluents (VAD) of varying pH 
x Borate saline (pH 9) 
x 0.4% Bovine albumin in borate saline (BABS) pH 9 
x Goose erythrocytes in Alsever’s solution 
x 0.9% Normal saline 
x Acid citrate dextrose 
x West Nile Virus antigens 
x 96 well ‘U’-bottom plate 
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x Miscellaneous- Cooling centrifuge, centrifuge tubes, pipettes (50ȝl and 
100ȝl), tips, polypropylene vials, test samples, tissue papers 
Preparation of Reagents 
Virus Adjusting Diluent (VAD) 
  Preparation of stock solutions 
(A)  1.5M Sodium chloride (Nacl): 87.65g of Sodium chloride in 100ml of 
distilled water and made to 1L  
(B) 0.5 M Boric acid: 30.92g of boric acid dissolved in 700ml hot distilled water 
and allowed to cool at room temperature, and made to 1L with double 
distilled water.  
(C) Concentrated Sodium Hydroxide (NaOH): 500ml of double distilled water 
added to 500g of sodium hydroxide pellets and the final concentration is 
18M 
(D) 0.5M Dibasic sodium phosphate: 70.99g of dibasic sodium phosphate 
dissolved in 100ml of distilled water and made to 1L. 
(E) 1M Monobasic sodium phosphate (NaH2PO4): 138.01g of monobasic sodium 
phosphate dissolved in distilled water and made to 1L. 
Table 5.3: Preparation the stock solution to be added for VAD 
STOCK SOLUTION pH 6.0 pH 6.2 pH 6.4 
1.5M sodium chloride 100ml 100ml 100ml 
0.5M dibasic sodium hydrogen phosphate 32ml 64ml 112ml 
1M monobasic sodium dihydrogen phosphate 184ml 169ml 144ml 
Distilled water 1L 1L 1L 
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Borate Saline (pH 9.0) 
1.5M sodium chloride  - 160ml 
0.5M boric acid   - 200ml 
1.0M sodium hydroxide   - 47ml   
The above mixture is made up to 2L with distilled water and pH adjusted to 
9.0 with 1M sodium hydroxide or with 0.5M boric acid and stored in refrigerator. 
0.4% Bovine Albumin in Borate Saline (BABS) 
0.4g of bovine albumin dissolved in 1000ml of borate saline (pH 9.0) and 
kept in refrigerator for overnight. pH is adjusted to 9.0 using 1M sodium hydroxide. 
Acid Citrate Dextrose 
Sodium citrate   - 11.26g 
Citric acid    - 40g 
Dextrose    - 11.0g 
Distilled water   - 500ml 
Prepared solution was sterilized by autoclaving. 
Normal Saline 
9.0g of sodium chloride dissolved in 1000ml of distilled water and sterilized 
by autoclaving. 
Alsever’s Solution 
Sodium citrate   - 4g 
Sodium chloride   - 2.1g 
Dextrose    - 10.25g 
Citric acid    - 0.55g 
Dissolved and made to 500ml with distilled water and steam sterilized 
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Goose Blood Collection 
x 45ml of acid citrate dextrose taken in a syringe fitted with a 20 gauge needle. 
x About 2.3ml of venous blood collected from the wing or the jugular vein. 
x The blood transferred to flask containing 3-4ml of alsever’s solution. 
x The suspension was mixed and stored at 4°C. 
Washing of Goose Erythrocytes 
x In centrifuge tube required quantity of erythrocyte suspension was taken and 
centrifuged at 2000rpm for 6 minutes. 
x The supernatant fluid and Buffy layer of WBC removed, without disturbing 
the packed RBC. 
x 2ml of normal saline was added and mixed. Then the suspension centrifuged 
at 2000rpm for 6 minutes. 
x  Repeat the above steps. 
x 10% suspension was made by removing the supernatant fluid and by adding 
sufficient quantity of saline based upon the volume of packed RBC. 
Treatment of Sera 
Test serum treated with acetone extraction procedure to remove the non-
specific inhibitors, and adsorbed with goose erythrocytes to remove natural 
agglutinins. 
Acetone Extraction of Sera 
x 0.9ml of normal saline and 0.1ml of serum added to 15ml centrifuge tube. 
x The tube placed in ice water bath and chilled acetone added and incubated 
for 5 minutes by mixing occasionally for precipitation. 
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x The tube centrifuged at 3000rpm for 6 minutes at 4°C, the supernatant was 
decanted and 10ml of fresh acetone was added and incubated for 60 minutes 
at 4°C. 
x The suspension was centrifuged at 4°C for 6 minutes at 3000rpm. The 
supernatant was discarded and the tube dehydrated in vacuum desiccator for 
1-2 hours. 
x 1ml of borate saline was added in to tubes and mixed well for complete 
rehydration of suspension. 
x The preparation was kept overnight at 4°C. 
Adsorption of Sera with Goose Erythrocytes 
x Acetone-extracted serum was kept in an ice bath and 0.1ml of washed goose 
erythrocytes was added to serum. 
x The suspension was centrifuged at 3000rpm for 15 minutes at 4°C. 
x The supernatant was separated in a 2ml polypropylene vial and stored in 
refrigerator until tested or stored at -20°C deep freezer for further use.  
Protocol 
x The 96 well ‘U’- bottom plate labeled as shown in the figure 5.6. 
x 50ȝl  BABS  (pH  9.0)  added  to  each  well  except  the  neat  column  and  plate  
chilled in fridge for few minutes. 
x 100ȝl virus isolates were added to the neat column. 
x 50ȝl from neat taken and two fold serial dilutions were made until the last 
well of that row and the last 50ȝl discarded. 
x 2.4ml of VAD of pH ranging from 6.0, 6.2 and 6.4 were taken. 
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x 0.1ml of 10% RBC added to each tube and mixed well, hence that is 0.45% 
of RBC. 
x BABS plus the cells suspended in respective VAD serves as cell control. 
x The plate was shaken gently and incubated room temperature till the cells in 
the control wells settled down (about 30 minutes). 
x The HA titre was recorded. 
Figure 5.6: 96 well ‘U’-bottom plate 
 N 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 
6.0             
             
6.2             
             
6.4             
             
             
C              
 
   pH 6.0    pH 6.2     pH 6.4 
 
N- Neat C- Control 
Immunofluorescence Assay   
The immunofluorescence assay was performed for the detection of virus 
from infected tissue culture fluids and the following materials were used for IFA.  
Materials 
. Immunofluorescent microscope 
. Teflon coated slides 
. Positive control 
. Negative control 
. Vero cell line 
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. 0.01M PBS  
. Buffered glycerol 
. Acetone 
. Anti-Rabbit FITC conjugate (DAKO) 
Reagents 
Phosphate Buffered Saline (PBS)  
Sodium Chloride - 7.0g 
Pottasium Chloride -  0.2g 
Pottasium Di Hydrogen  
Phosphate  - 0.2g 
Di Sodium Hydrogen 
Phosphate  - 1.5g 
pH    -  7.2 
All the above ingredients were dissolved in 1000ml of distilled water and 
autoclaved. 
Buffered glycerol 
Glycerol -  9ml 
PBS  -  1ml 
pH   -  7.2 
Methodology 
x The   PCR  positive  CSF  samples  were  inoculated  in  Vero  cell  line  and  
incubated at 37qC. 
x After 7 days CPE was observed the cells were scrapped and a smear was 
made on the marked area of glass slide.  
x The slides were fixed with chilled acetone for 15 minutes at room 
temperature. 
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x 20ȝl of 1:10 flavivirus cross reactive monoclonal antibodies (NIV, Pune) 
were added on the smear and incubated in humidified box at 37qC for 30 
minutes followed by several washes with PBS(pH 7.2). 
x 20ȝl of 1:10 anti-mouse IgG FITC conjugate was added to the smear and 
incubated at 37qC in humidified box and incubated at 37qC for 30 minutes. 
x Smear air-dried and mounted with buffered glycerol mounting medium and 
observed under immunofluorescent microscope for intracytoplasmic apple 
green fluorescence. 
5.4 DEVELOPMENT AND STANDARDIZATION OF PAN-FLAVIVIRUS  
 DETECTION SYSTEM 
In the present study the conserved amino acid sequences among Japanese 
Encephalitis, Dengue and West Nile viruses were identified and the peptide having 
the conserved amino acid sequence was used to generate polyclonal antibodies in 
mice module and these antibodies were used to detect those flaviviruses. 
Identification of flavi-specific epitope 
Amino acid sequences of envelope protein of several flaviviruses were 
downloaded from NCBI databank. Amino acid sequences were edited and analyzed 
by the Laser gene software package V5.0 (DNASTAR Inc, USA). Multiple 
sequence alignments were carried out employing CLUSTAL W version 1.83. 
Synthesis of peptide 
The flavi-specific conserved amino acid sequence was found to be 
“DRGWGNGCGLFGKG”. The identified peptide is custom synthesized by Sigma-
Aldrich Company. The purity and homogeneity of the synthesized peptide was 
analyzed by RP-HPLC, which can separate peptides of even one amino acid 
difference based on differences in surface hydrophobicity. The synthesized peptide 
was dissolved in triple distilled sterile water so as to achieve a final concentration of 
1 mg/ml and stored at -20°C till used. 
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Structural and physico-chemical characterization of the peptide 
The synthesized peptide was analyzed by reverse phase HPLC. MALDI-MS 
analysis of peptide will be done following the protocol of Brown and Lennon. 
Predictive analysis of the peptide  
Predictive structural analysis of the peptide was carried out using RasWin 
Molecular Graphics. Antigenicity, hydrophilicity and secondary structure of the 
peptide will be predicted using ProteanTM. 
Animals and immunization 
Mice used in this study were obtained from the animal facility of the KIPM, 
Chennai. Mice were housed, fed and used in experiments according to the guidelines 
set forth in the guidelines for the production of antibodies in laboratory animals 
(Animal Care and Use Program, University of California, Berkeley). Swiss Albino 
mice of 3-4 weeks old were immunized by the subcutaneous route with 50µg/ml 
concentration of peptide emulsified in with Freund's complete adjuvant. The mice 
(25-30g) were procured from the King Institute of Preventive Medicine and 
Research, Guindy, Chennai, India. The animals were housed separately in 
polypropylene cage at temperature of 23 ± 2ɨ C and 50-60% relative humidity, with 
a 12h light/dark cycle respectively, for one week before and during the 
commencement of experiment in the department of virology, KIPM & R, Guindy, 
Chennai. Animals were allowed to access standard rodent pellet diet and drinking 
water. Food was withdrawn 18-24h before the experiment, though water was 
allowed adlibitum and allocated to different experimental groups. All experimental 
procedures involving animals were conducted in accordance with the guidelines of 
Committee for the Purpose of Control and Supervision on Experiments on Animals 
(CPCSEA). The study protocols were approved by Institutional Animal Ethics 
Committee (IAEC) of KIPM & R, Guindy, Chennai. 
The animals were divided into 3 groups, each group constituting 5 mice.  
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Group-1: Control  
Group-2: Immune peptide 100 mg/kg  
Group-3: Immune peptide 50 mg/kg  
The peptide was administered through subcutaneous injection. The mice 
were observed for acute toxicity up to 8 days.  
The animals were boosted on days 28, 53 and 150 days. Sera were collected 
at 14 days after immunization.  
Histopathological Studies  
After the duration of the experiment, the tissues like heart, lungs, liver and 
kidney were fixed in 10% neutral formalin for 24 hours. Cut sections by razor. Wash 
the fixatives first with tap water and then in the distilled water. Dehydrate in graded 
alcohols. Clear in xylene. The tissues were embedded in paraffin wax, made block 
and cut sections of 5 micron thickness, stained and mounted the slides in D.P.X. 
Sections were dewaxed in xylene for 5 minutes. Hydrated to water through 
descending  grades  of  alcohol  series  with  two minutes  intervals  in  each  series.  The  
sections were stained with in haematoxylin for 20-30 minutes. Place the slides in tap 
water for 5 minutes. Differentiated in acid- alcohol with a quick dip of slides into the 
solution. Again dip in tap water until the sections were counter stained with eosin for 
3-5 minutes. The sections were dehydrated in ascending grades of alcohol series 
with 5 minutes intervals in each series, cleared completely in xylene for 1 minute 
mounted in DPX. Microphotographs were taken using a Topcon RE 200 camera 
(Japan) attached to the microscope (Olympus). 
Standardization of Pan-flavi ELISA 
Mice hyper-immune sera were used for recognition of peptide by ELISA. 
Briefly, wells of a microtitre plate were coated with 1ȝg of peptide and blocked with 
5% skimmed milk powder solution in phosphate-buffered saline (blocking buffer). 
Antigen-coated wells were incubated for 90 minutes at 37°C with 100ȝl of mice 
serum diluted in blocking buffer. Serial two fold dilutions of sera starting with 1:10 
95 
 
were used. After washing with PBS containing 0.05% Tween 20, 100ȝl of 
horseradish peroxidase-labeled anti-mouse IgG antibody conjugate diluted 1:2000 
was added to each well and incubated for 60 minutes at 37°C. The color reaction 
was developed with tetramethyl bezidine substrate.The reaction was stopped by 
addition of 1N sulfuric acid and OD was recorded at 490nm in a microplate ELISA 
reader. Pre-immune sera as well as sera raised against adjuvant alone were used with 
similar dilutions as controls. 
Dot-ELISA 
Mice hyper-immune sera were also used for detection of flaviviruses by dot-
ELISA. Briefly, Nitrocellulose strips (NC strips) were coated with heat inactivated 
virus suspension of flavivirus epitope. The coated strips were blocked and kept 
standing  in  wells  of  micro  titre  plates  filled  with  various  dilutions  of  mice  serum.  
The conjugate was added and results were analyzed. Pre-immune sera as well as sera 
raised against adjuvant alone were used with similar dilutions as controls. NC strips 
were dried and observed for the appearance of brown color dots. 
Reagents used in the study 
Analytical, tissue culture and molecular grade fine chemicals used in this 
study were obtained from following firms-Sigma chemical company, GIBCO BRL, 
Life technologies, USA, SRL India and Hi Media.  
Viral RNA extraction kit was procured from Qiagen. Enzymes and molecular 
markers used in the study were obtained from Bio Labs New England inc. 
Equipments used in this study 
 Name      Manufacturer 
1. Inverted microscope   -  Nikon 
2. Immunofluorescence microscope  -  Nikon 
3. ELISA reader & washer   -  Thermo lab system 
4. Centrifuge     -  Eppendorf and Remi 
5. CO2 Incubator    -  Binder 
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6. Vortex mixer    -  Remi 
7. Micropippettes    -  Gilson / Finn pipette  
8. Thermocycler    -  Applied Biosystems 
9. Gel documentation system   -  Alpha imager    
Statistical analysis  
The Data was statistically analyzed by the software SPSS.20 IBM version. 
Specific  type  distribution  was  assessed  by  ANOVA  and  post  hoc  Dunnet  analysis  
were performed in various variables such as sex, age, month and positivity were 
performed.  Degrees  of  freedom  were  set  as  0.05  level.  Comparison  with  different  
viral species was analyzed. Further Linear regression were performed for year wise 
analysis of significance in samples. Ms-Excel was used for the graphical plotting of 
variables in different year and seasons using standard error mean. 
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RESULTS AND ANALYSIS 
 
6.1  SEROPREVALENCE 
The suspected AES cases (collected after 4 days of onset) referred from 
different hospitals of Tamil Nadu were screened for Japanese Encephalitis, Dengue 
and West Nile viruses by IgM Capture ELISA. The positivity of JEV, DENV and 
WNV were tabulated in the table 6.1 and 6.2. 
Table 6.1: Results of Serum IgM ELISA 
Year Total No. of samples screened 
JE 
Positive 
Dengue 
Positive 
WNV 
Positive 
2011 218 12 5 3 
2012 505 35 14 2 
2013 936 45 21 4 
2014 900 35 20 4 
 
Table 6.2: Results of CSF IgM ELISA 
Year Total No. of samples screened 
JE 
Positive 
Dengue 
Positive 
WNV 
Positive 
2011 76 2 2 1 
2012 294 12 7 2 
2013 713 23 15 2 
2014 709 10 17 2 
 
In the study, the percentage positivity of JEV, DENV and WNV viruses were 
calculated and presented in the figure 6.1. Among the three viruses, JE virus showed 
higher prevalence than Dengue and West Nile viruses. Though the number of 
98 
 
samples increased during the study period there was not a significant difference in 
the percentage positivity shown in the figure 6.1.  
Figure 6.1: Year wise Distribution of JE, Dengue and West Nile virus  
(2011-2014) 
 
 
 
 
 
 
 
 
 
 
 
Highest percentage positivity was observed in the year 2012 and it was 
decreased afterwards. The similar trend was also observed for CSF samples 
regarding Dengue and West Nile viral infections. 
Epidemiology and Incidence of flavivirus causing Acute Encephalitis Syndrome 
(AES) in Tamil Nadu 
 The suspected AES cases were screened for the incidence of flaviviruses 
such as Japanese Encephalitis, Dengue and West Nile viruses in various districts of 
Tamil Nadu during the period of 2011-2014. The district wise distributions of 
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positive cases were represented in the figure 6.1a. The positive cases of JE were 
investigated in fourteen districts of Tamil Nadu (Figure 6.1a).  
Figure 6.1a: Tamil Nadu map showing District wise distribution of JE, West 
Nile and Dengue virus 
 
 
Similarly the positive cases of Dengue virus were represented in seven 
districts and West Nile viruses were represented in eight districts of Tamil Nadu as 
shown in figures 6.1 and Table 6.3-6.5. 
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Table 6.3: District-wise distribution of Laboratory confirmed positive cases of 
JE from 2011-2014 
S.No District 2011 2012 2013 2014 
1 Chennai. 2 9 13 7 
2 Thiruvallur. 13 6 8 9 
3 Kanchipuram. 5 7 10 6 
4 Thiruvannamalai. 0 2 4 2 
5 Villupuram. 0 1 0 2 
6 Cuddalore. 0 1 2 0 
7 Thanjavur. 1 2 4 1 
8 Ariyalur. 0 1 1 0 
9 Perambalur. 0 0 1 1 
10 Vellore. 1 3 1 2 
11 Trichy. 0 1 0 1 
12 Madurai. 0 1 0 1 
13 Thirunelveli. 0 0 1 2 
14 Erode. 0 1 0 1 
 
The maximum positive AES cases of JE and Dengue were reported in 
Chennai, Thiruvallur and Kanchipuram districts of Tamil Nadu. The higher positive 
AES cases of West Nile virus were explored in Thiruvannamalai, Chennai and 
Thiruvallur districts. 
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Table 6.4: Districtwise distribution of Laboratory confirmed positive cases of 
Dengue from 2011-2014 
S.No District 2011 2012 2013 2014 
1 Chennai. 1 0 0 1 
2 Thiruvannamalai. 1 0 1 1 
3 Kanchipuram. 0 1 0 0 
4 Vellore. 0 1 0 0 
5 Krishnagiri 1 0 1 0 
6 Madurai 0 0 1 1 
7 Thanjavur 0 0 0 1 
8 Cuddalore 0 0 1 0 
 
Table 6.5: District-wise distribution of Laboratory confirmed positive cases of 
West Nile from 2011-2014 
S.No District 2011 2012 2013 2014 
1 Chennai. 2 5 7 5 
2 Thiruvallur. 2 3 3 2 
3 Kanchipuram. 1 2 5 8 
4 Thiruvannamalai. 0 2 2 1 
5 Thanjavur. 0 1 2 0 
6 Virudhunagar 0 0 1 3 
7 Theni 0 1 1 1 
 
6.3 AGE WISE DISTRIBUTION OF AES CASES 
 Samples representing different age groups such as 0-12, 12-18, 18-35, 35-55 
and above 55 were segregated. The prevalence in different age groups were 
statistically analyzed and represented in the figure 6.2-6.4 by standard error mean. 
Among the various age groups, the positivity was predominantly seen in the 
pediatric age group during the study period. Few positive cases were observed in 
young adults. During the period 2013 and 2014, positivity was observed in adults 
and geriatric age group.  
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Figure 6.2: Epidemiological study of JEV during the year 2011-2014. 
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Figure 6.3: Epidemiological study of Dengue virus during the year 2011-2014.
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 Figure.6.4. Epidemiological study of WNV during the year 2011-2014 
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The total suspected cases were statistically analyzed using linear regression 
in different periods from 2011 to 2014. The linear regression in the figure 6.5 
suggested that there is an increase in sample size and the total number of suspected 
cases linearly raised from 2011 to 2014. In comparison of three viruses in AES cases 
showed that high number of samples were received for Dengue. The positivity of all 
the flaviviruses in AES cases the study period 2011-14 was in the order of JEV > 
Dengue >West Nile viruses. 
 But the regression scatter plot in the figure 6.5. A - C showed that there was 
an increase in the number of cases for all flaviviral infections though there was not 
much change in the percentage positivity. The multiple comparison analysis of the 
study period infers the higher number of positivity was observed in 2013 than 2014. 
Figure 6.5: Linear Regression analysis of Positive caes of JE, Dengue and West 
Nile viruses from 2011-2014 
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The Post hoc Dunnet statistical analysis inferred that there was significant 
difference within the group and there was no significant difference between the 
groups Table. 6.6 to 6.11. The one way ANOVA analysis of different age groups of 
(JEV,  DENV  and  WNV)  cases  were  analyzed  in  different  periods  of  the  year  
showed in the table 6.6, 6.8, 6.10. The mean difference was significant in all the age 
groups with degrees of freedom 0.05 level.  
Table 6.6: Statistical Analysis (ANOVA) of Japanese Encephalitis virus during 
2011-2014 
Dependent Variable Mean Square F Sig. 
Male  Between Groups  3101.833 9.636 .000 
Within Groups  321.890   
Female  Between Groups  1880.799 11.412 .000 
Within Groups  164.809   
Positives  Between Groups  22.083 2.807 .055 
Within Groups  7.867   
Negatives  Between Groups  9896.806 10.753 .000 
Within Groups  920.352   
zeroto12yr  Between Groups  3832.132 8.636 .000 
Within Groups  443.737   
Thirteen to 19yrs  Between Groups  61.076 4.810 .006 
Within Groups  12.699   
Twenty to 35yrs  Between Groups  187.910 6.732 .001 
Within Groups  27.911   
Thirty six to 55yrs  Between Groups  3.806 1.245 .305 
Within Groups  3.057   
Above 55yrs  Between Groups  5.076 4.678 .006 
Within Groups  1.085   
 
* The mean difference is significant at the 0.05 level.   
a. Dunnett t-tests treat one group as a control, and compare all other groups against  
    it. 
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Table 6.7: Post hoc Dunnet Analysis of Japanese Encephalitis virus during 
2011-14 
Dependent Variable Std. Error Sig. 
Male Dunnett t (2-sided)a 2011-12 
2012-13 
2013-14 
 
7.32450 .000 
7.32450 .024 
7.32450 .986 
Female Dunnett t (2-sided)a 2011-12 
2012-13 
2013-14 
5.24100 .000 
5.24100 .048 
5.24100 .995 
Positives Dunnett t (2-sided)a 2011-12 
2012-13 
2013-14 
1.40243 .082 
1.40243 .968 
1.28023 .999 
Negatives Dunnett t (2-sided)a2011-12 
2012-13 
2013-14 
12.38515 .000 
12.38515 .030 
12.38515 .983 
zeroto12yr Dunnett t (2-sided)a2011-12 
2012-13 
2013-14 
8.59977 .126 
8.59977 1.000 
8.59977 .011 
Thirteen to 19yrs Dunnett t (2-sided)a 2011-12 
2012-13 
2013-14 
1.45481 .267 
1.45481 1.000 
1.45481 .089 
Twenty to 35yrs Dunnett t (2-sided)a2011-12 
2012-13 
2013-14 
2.15681 .355 
2.15681 1.000 
2.15681 .014 
Thirty six to5 5yrs Dunnett t (2-sided)a2011-12 
2012-13 
2013-14 
.71377 .888 
.71377 1.000 
.71377 .439 
Above 55yrs Dunnett t (2-sided)a 2011-12 
2012-13 
2013-14 
.42529 .284 
.42529 1.000 
.42529 .093 
 
*. The mean difference is significant at the 0.05 level.  
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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Table 6.8: Statistical Analysis (ANOVA) of Dengue virus during 2011-14. 
Variables Mean Square F Sig. 
Male Between Groups 3101.833 9.636 .000 
Within Groups 321.890   
Total    
Female Between Groups 1880.799 11.412 .000 
Within Groups 164.809   
Total    
Positives Between Groups 1.612 1.562 .221 
Within Groups 1.032   
Total    
Negatives Between Groups 9896.806 10.753 .000 
Within Groups 920.352   
Total    
zeroto12yr Between Groups 3832.132 8.636 .000 
Within Groups 443.737   
Total    
Thirteen 
to19yrs 
Between Groups 61.076 4.810 .006 
Within Groups 12.699   
Total    
Twenty to 35yrs Between Groups 187.910 6.732 .001 
Within Groups 27.911   
Total    
Thirty six to 
55yrs 
Between Groups 3.806 1.245 .305 
Within Groups 3.057   
Total    
Above 55yrs Between Groups 5.076 4.678 .006 
Within Groups 1.085   
Total    
 
*. The mean difference is significant at the 0.05 level  
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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Table 6.9: Post hoc Dunnet Analysis of Dengue virus during 2011-14 
Dependent Variable Std. Error Sig. 
Male  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
7.32450 .000 
7.32450 .024 
7.32450 .986 
Female  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
5.24100 .000 
5.24100 .048 
5.24100 .995 
Positives  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
.60109 .387 
.48194 .994 
.46683 .667 
Negatives  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
12.38515 .000 
12.38515 .030 
12.38515 .983 
Zero to 12 yr  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
8.59977 .126 
8.59977 1.000 
8.59977 .011 
Thirteen to 19 
yrs  
Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
1.45481 .267 
1.45481 1.000 
1.45481 .089 
Twenty to 35 yrs  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14 
2.15681 .355 
2.15681 1.000 
2.15681 .014 
Thirty six to 55 
yrs  
Dunnett t (2-sided)
a
2011-12 
2012-13 
2013-14 
.71377 .888 
.71377 1.000 
.71377 .439 
Above 55 yrs  Dunnett t (2-sided)
a
 2011-12 
2012-13 
2013-14  
.42529 .284 
.42529 1.000 
.42529 .093 
 
*. The mean difference is significant at the 0.05 level.  
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.  
 
 
110 
 
Table 6.10: Statistical Analysis (ANOVA) of West Nile virus during 2011-14 
Variables Mean Square F 
Male Between Groups 3101.833 9.636 
Within Groups 321.890  
Total   
Female Between Groups 1880.799 11.412 
Within Groups 164.809  
Total   
Positives Between Groups .000 . 
Within Groups .000  
Total   
Negatives Between Groups 9896.806 10.753 
Within Groups 920.352  
Total   
zeroto12yr Between Groups 3832.132 8.636 
Within Groups 443.737  
Total   
Thirteento19yrs Between Groups 61.076 4.810 
Within Groups 12.699  
Total   
Twentyto35yrs Between Groups 187.910 6.732 
Within Groups 27.911  
Total   
thirtysixto55yrs Between Groups 3.806 1.245 
Within Groups 3.057  
Total   
Above55yrs Between Groups 5.076 4.678 
Within Groups 1.085  
Total   
 
*. The mean difference is significant at the 0.05 level.  
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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Table 6.11: Post hoc Dunnet Analysis of West Nile virus during 2011-14 
Dependent Variable Std. Error Sig. 
Male  Dunnett t (2-sided)a 
2011-12 
2012-13 
2013-14 
7.32450 .000 
7.32450 .024 
7.32450 .986 
Female  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
5.24100 .000 
5.24100 .048 
5.24100 .995 
Negatives  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
12.38515 .000 
12.38515 .030 
12.38515 .983 
zeroto12yr  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
8.59977 .126 
8.59977 1.000 
8.59977 .011 
Thirteento19yrs  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
1.45481 .267 
1.45481 1.000 
1.45481 .089 
Twentyto35yrs  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
2.15681 .355 
2.15681 1.000 
2.15681 .014 
Thirty six to55yrs  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
.71377 .888 
.71377 1.000 
.71377 .439 
Above55yrs  Dunnett t (2-sided)a  
2011-12 
2012-13 
2013-14 
.42529 .284 
.42529 1.000 
.42529 .093 
 
*. The mean difference is significant at the 0.05 level.  
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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6.4 SEASON WISE DISTRIBUTION OF AES CASES 
 The  season  wise  distribution  of  cases  was  statistically  analyzed  for  their  
epidemiological characterization of the AES. The inference of the seasons of AES 
susceptibility was represented in the figure 6.6. Among the three flaviviruses, the 
highest positive cases were due to Japanese Encephalitis viral infection in all the 
seasons except pre monsoon. The Dengue viruses have highest positive cases in the 
South  West  and  North  East  monsoon  seasons.  Susceptible  cases  were  found  to  be  
lower during the winter and pre monsoon than other seasons. The positive cases due 
to West Nile viral infection were higher in the South West monsoon than other 
seasons.  On  the  whole,  the  JE  viral  infection  was  found  to  be  frequent  during  the  
study period 2011-14 when compared to Dengue and West Nile viral infections. 
Figure 6.6: Season wise distribution of JE, Dengue and West Nile virus from 
2011-2014.  
 
 
 
 
 
 
 
 
 
JE 
Dengue 
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6.5 GENDER WISE DISTRIBUTION OF JE, DENGUE AND WEST NILE  
 VIRUSES  
 The gender wise distribution of positive cases were statistically analyzed for 
Japanese Encephalitis, Dengue and West Nile viruses. The month wise and gender 
wise analysis were done and represented in the figure 6.2 to 6.4. The susceptible 
cases were frequently observed in the month of October, November and December 
during the study period. The positive cases of flaviviruses were low in the 2011 and 
2014 figure 6.1. Among the three falaviviruses, the Japanese Encephalitis cases 
occurred more than the West Nile and Dengue viruses. Gender wise analysis 
indicated that positives and susceptible cases were high in males than females.  
6.6 MOLECULAR CHARACTERIZATION OF JE, DENGUE AND 
WEST NILE VIRUSES 
 Totally, 324 CSF samples were subjected to Pan-flavi conventional 
polymerase  chain  reaction  (PCR).  Among  them,  24  samples  were  confirmed  as  
positive for Pan-flavi  PCR characterized by the amplified product of 655bp (Figure 
6.6).  
 
Figure 6.6: Agarose gel analysis of Pan-flavi  RT-PCR. Lane 1. Molecular 
weight marker; Lane 2 to Lane 6 samples; Lane 7. Negative control; Lane 
8.Positive control 
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Further, the positive samples were amplified using specific primers for 
Japanese Encephalitis (JEV) characterized by the amplified product of 241bp  
(Figure 6.7). 
Figure 6.7: Agarose gel analysis of JEV RT-PCR. Lane 1. Molecular weight 
marker; Lane 2 to Lane 6 samples; Lane 7. Negative control; Lane 8.Positive 
control 
 
Dengue positives were first subjected to Pan Dengue characterized by the 
amplified product of 511bp then it was further segregated for D3 and D4. The 
Dengue (DENV-3) was characterized by the amplified product of 288bp (Figure 
6.8), D4 260bp (Figure 6.9) and West Nile viruses (WNV) characterized by the 
amplified product of 396bp (Figure 6.10).  
Figure 6.8: Agarose gel analysis of Pan Dengue RT-PCR. Lane 1. Molecular 
weight marker; Lane 2 to Lane 6 samples; Lane 7. Negative control; Lane 
8.Positive control 
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Figure 6.9: Agarose gel analysis of Pan Dengue-3 & 4 RT-PCR lane. 1. 
Molecular weight marker;Lane 2 to Lane 6 samples; Lane 7. Negative control; 
Lane.8. Positive control 
 
 
 
 
 
 
 
 
 
Figure 6.10: Agarose gel analysis of West Nile RT-PCR. Lane 1. Molecular 
weight marker; Lane 2 to Lane 6 samples; Lane 7. Negative control; Lane 
8.Positive control 
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Of the 24 positive cases, 15, 6 and 3 samples were positive for JEV, DENV 
and WNV respectively Table 6.11. More number of CSF cases was occurred in the 
years 2013 and 2014. Finally the positive samples were subjected to sequence 
analysis for further molecular characterization. During the study period, the 
Japanese Encephalitis virus was found to be the most predominant flavivirus among 
the three flaviviruses. The positive CSF cases of all flaviviruses were predominant 
among the age group of pediatric and adolescent. 
Table 6.11: Year wise positive results of PCR in CSF  
 
Year Total samples  Positive JE Positive 
Dengue 
Positive 
WNV 
Positive 
2011 24 0 0 0 0 
2012 65 8 5 2 1 
2013 111 12 8 3 1 
2014 124 4 2 1 1 
 
6.7 VIRUS ISOLATION AND CHARACTERIZATION BY  
 HAEMAGGLUTINATION 
 The PCR positive samples were subjected to virus isolation using Vero cell 
lines.  The  PCR  positives  of  the  flaviviruses  (JEV,  DENV,  WNV)  showing  
cytopathic effect were represented in the figure 6.11.  
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Figure 6.11: Cytopathic effect of JEV, DENV and WNV in Vero cell 
line A: Control, B: JE infected cells, C: Dengue infected cells,  
D: West Nile infected cells  
 
 
The isolated JE virus was more compatible in the early passages of 2 and 4, 
rest of the passages were less sensitive and less specific. The Dengue virus was more 
compatibly isolated in the late 6th passage. West Nile virus was isolated from the 
infected  Vero  cells  up  to  5th passage  of  cell  culture.  The  virally  infected  cells  
exhibited CPE representing the changes in cellular architecture such as cell 
rounding, shrinkage and enlargement between the cells expresses as gaps in the 
figure 6.11B, C & D and the virus infected cells were then subjected to 
haemagglutination in different pH (6, 6.2 and 6.4). The optimum pH for the haem-
agglutination of the flaviviruses were represented in the figure 6.12. The optimum 
pH of Haem-Agglutination in JE virus was optimally agglutinated at pH 6.2, shown 
in the figure 6.12 Similarly, the Dengue and West Nile viruses agglutinated well at 
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the  optimum  pH  of  6.4.  The  viral  titre  of  JE  viruses  was  optimally  observed  as  
1:128. Similarly the Dengue viruses showed the optimum titre of 1:256 and West 
Nile virus 1:32. 
Figure 6.12: Haemagglutination assay.A: JEV, B: DENV, C: WNV 
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6.8 IMMUNOFLUORESCENCE ASSAY FOR JE, DENGUE AND WEST 
NILE VIRUS 
 Further characterization of flaviviruses were carried out by 
Immunofluorescence Assay (IFA). The IFA results of the viral infection of cells 
were represented in the figure 6.13. The figure shows the determination of positive 
and negative by the subsequent appearance of virus by antihuman IgM antibody 
fluorescent tag. The JE positive IFA was clearly appeared as apple green colour. The 
uninfected cells was observed as cherry red colour due to the non adherent binding 
of anti human IgM antibody fluorescent tag shown in figure 13A. Similarly the 
Immunofluorescence  Assay  (IFA)  of  Dengue  virus  was  showh  in  figure  13B   and  
West Nile virus displayed in figure 13C. The dilution of 1:10 stains good 
fluorescence intensity with less noise in the background.  
 
Figure 6.13: Immunofluorescence Assay. A:JEV, B: DENV, C: WNV 
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6.9  MOLECULAR PHYLOGENY AND SEQUENCE ANALYSIS OF  
 JAPANESE ENCEPHALITIS VIRUS ISOLATES 
 The amplicons were purified using QIA quick PCR purification kit (Qaigen) 
and subjected to cycle sequencing using ABI Prism Big Dye Terminator V3.1 cycle 
sequencing kit. Post-cycle sequencing purification was performed using Dye Ex2.0 
spin kit (Qiagen). Sequencing was performed on ABI Prism 310 and sequence 
alignment and phylogenetic analyses were done using Mega version 6.  
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The nucleotide sequencing of JEV were presented in the figure and the 
sequence was deposited with the accession number from Gene Bank of National 
Center for Biological Information (NCBI) were assigned and presented in the figure 
6.14.  The figure 6.15 & 6.16 represents the phylogenetic tree derived from the gene 
sequences of JEV 1 and 2 along with wild isolates.  
The phylogram showed 1 and 2 gene sequences of the isolates [Genbank: 
KJ947880] belonging to the non-structural protein -5 gene and comprising 98% - 
100% nucleotide similarity with each other. The rooted tree of JE current sequence 
analysis shows that the phylogram have a common ancestor of gene sequence 
belonging to India gi|496909/India/2005/envelope. The KIPM JE sequences were 
highly homologous with the clade of Indian sequences 2009 and 2011 
gi|239633849/India/2009/ envelope and gi|289466091/India/2011/envelope.  
The phylogenetic distances between the two close sequences  
with the query sequences was calculated in the Mega and found as 0.021.  
The second close clade of JE/TN/ KIPM sequences have 96% higher similarity with 
US, China and Japan with accession number of gi|1778238 / USA / 1997 / envelope, 
gi|410026435/China/2014/envelope and gi|52546172/Japan/2009/ polyprotein 
shown in the figure.6.16. The phylogenetic distance was calculated in the second 
clade and it was found to be 0.0148. 
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Figure 6.14: Sequencing and deposition of Japanese Encephalitis virus isolates 
in NCBI 
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Figure 6.15: Radial phylogenetic tree of Japanese Encephalitis virus 
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Figure 6.16: Phylogenetic analysis of Japanese Encephalitis virus representing 
phylogram 
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6.10 MOLECULAR PHYLOGENY AND SEQUENCE ANALYSIS OF 
DENGUE-3 AND DENGUE- 4 ISOLATES 
The KIPM DENV 3 sequence was submitted in NCBI and  
accessesion number showed in figure 6.17 & 6.18. It was highly  
homologous with the clade of Taiwan (gi/ 25992032/Taiwan/2006/Polyprotein) 
(gi/25992032/Taiwan/2006/Polyprotein), Peru (gi/19071812 peru/2002/capsid) and 
Sri Lanka (gi 164654854 srilanka/2015/Anchored). The above clades were highly 
close to the KIPM KJ947880. The phylogenetic distances between the closely 
related sequences and the query sequence was calculated using Mega and found to 
be 0.0425 (Figure 6.19 & 6.20). 
 The second close clade of Dengue KIPM sequences have 96% higher 
similarity with Brazil and other parts of Indian sequences of Maharashtra 
(gi|574486451/India/Maharashtra/2014/polyprotein) and Thailand (gi|116874465/ 
Thailand/2011/polyprotein). The phylogenetic distance was calculated in the second 
clade and it was found to be 0.0158. Similarly, the Dengue 4 sequences were highly 
homologous with the clade of  Manila (gi|923096874/Manila/2015/polyprotein) and 
Finland (gi|675895418/ Finland/2014/polyprotein).  
The above clades were closely related to the KIPM 732562361 sequences. 
The phylogenetic distances between the closely related sequences  
with that of the query sequence was calculated in the Mega and it was found to be 
0.0486. The second close clades of Dengue KIPM sequences have 94-96%  
higher similarity with Brazil (gi|443909555/Brazil/2013/polyprotein),  
Japan (gi|321117306/Japan/2011/polyprotein) and Germany (gi|5823462/Germany/ 
1999/polyprotein). The phylogenetic distance between the groups of sequences in 
the second clade was found to be 0.0312 (Figure 6.20). 
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Figure 6.17: Sequencing of Dengue 3 virus isolate and deposition in NCBI 
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Figure 6.18: Sequencing of Dengue-4 virus isolate and deposition in NCBI 
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Figure 6.19: Radial phylogenetic tree of Dengue-3 virus isolate 
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Figure 6.20: Phylogenetic analysis of Dengue-3 representing phylogram 
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6.11 MOLECULAR PHYLOGENY AND SEQUENCE ANALYSIS OF  
 WEST NILE VIRAL ISOLATES 
 The PCR amplicons of West Nile viruses were purified using QIAquick PCR 
purification kit (Qaigen) and subjected to cycle sequencing using ABI Prism Big 
Dye terminator V3.1 cycle sequencing kit. Post-cycle sequencing purification was 
done using Dye Ex 2.0 spin kit (Qiagen). WNV Sequencing was performed on ABI 
Prism 310 and sequence alignment and phylogenetic analyses were done using Mega 
version 6. The nucleotide sequencing of WNV were presented in the figure.6.21 & 
6.22 and the sequence was deposited with the accession number from Gene Bank of 
NCBI.  
The figures 6.23 & 6.24 represents the phylogenetic tree derived from the 
gene sequences of WNV 1 and 2 along with wild isolates. The phylogram showed 1 
and 2 gene sequences of the isolates [Genbank: KP170483 and KP170484] 
belonging to the Polyprotein gene and comprising 98%-100% nucleotide similarity 
with each other. The rooted tree of WNV current sequence analysis shows that the 
phylogram have the common ancestor of gene sequence belonging to USA 
Polyprotein (gi|260533850/USA/2009/polyprotein).  
The KIPM WNV sequences were highly homologous with the clade of 
Madagascar (gi|58618099/ Madagascar/2006/polyprotein) and USA (gi|27735298/ 
USA/2012/unnamed) shown in the figure 6.23. The phylogenetic distances of 
sequences with the query sequence was calculated using the Mega and it was found 
to  be  0.021.  The  second  close  clade  of  WNV/TN/  KIPM  sequences  have  96%   
higher similarity with Israel (gi|290246783/Israel/2011/polyprotein) and USA 
gi|158516889/USA/2015/ unnamed) shown in the figure 6.23 of radial tree. The 
phylogenetic distance was calculated in the second clade and it was found to be 
0.0133. 
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Figure 6.21: Sequencing of West Nile virus isolate and deposition in NCBI 
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Figure 6.22: Sequencing of West Nile virus isolate and deposition in NCBI 
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Figure 6.23: Phylogenetic analysis of West Nile virus representing phylogram 
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Figure 6.24: Radial phylogenetic tree of West Nile virus isolate 
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6.12 DEVELOPMENT AND STANDARDIZATION OF PAN-FLAVI 
DETECTION SYSTEM IN SWISS ALBINO MICE MODEL  
The common conserved sequences of pan-flaviviruses were evaluated for the 
toxicity and immune response to develop diagnosis for viruses in mice model 
represented in the figure 6.25.  
 
Figure 6.25: Intramuscular Administration of Fusogenic peptide in Swiss 
albino mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similarly, in the mice model the synthetic peptide of pan-flavi common 
conserved sequences (Figure 6.27) of  DENV, JEV and WNV were mined using the 
Clustal W tools and designed for peptide synthesis.  
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Figure 6.26: Multiple sequence alignment of flaviviruses by Clustal W tool 
 
 
 
 
 
 
 
 
 
 
 
Then, the designed fusogenic peptide was evaluated in vivo through the 
Swiss Albino mice model. The mice were initially administered 100µg 
intramuscularly in 21 days old mice with 20g body weight shown in the figure 6.25. 
The LD50 was found to be 100µg. Further, the effective concentration was calculated 
and it was found to be 50µg. All the treated groups were sacrificed in the end of the 
booster dose of synthetic peptide administered as per the standard immunization 
protocol. Then the liver, spleen, heart and kidney were subjected for the 
histopathological observation presented in the figure 6.27. The liver treated with the 
synthetic fusion peptide and control were compared and represented in the figure 
6.27A. The control liver displays the normal cellular architecture. But in the fusion 
peptide treated liver showed the massive necrosis and alteration in the hepatocytes 
shown in the figure 6.27B.  
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Figure 6.27: Histopathological study of Fusogenic peptide (from 
flavivirus) in swiss albino mice 
A: Control liver, B: Fusogenic peptide treated liver, C: Control lungs  
D; Fusogenic peptide treated lungs. 
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Figure 6.28: Histopathological study of Fusogenic peptide (from flavivirus) in 
swiss albino mice  
 
A: Control Spleen, B: Fusogenic peptide treated Spleen,  
C: Control Heart D: Fusogenic peptide treated Heart 
 
 
 
  
 
 
 
 
 
 
 
 
 
Similarly, the fusion peptide treated spleen showed that the alteration and 
lesions in the spleen of the mice displayed in the figure 6.28D. The control spleen 
showed the normal architecture and no such damage was seen in the control spleen 
(Figure 6.28C). The spleen and heart were abruptly damaged the spleenocytes were 
damaged well in the spleen and the cardio cells and the myocytes in the heart was 
damaged. Fusion peptide treated heart showed there was a massive damage in the 
cytoplasmic cells.  
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The fusion peptide treated lungs showed the disorted alveolar morphology 
(Figure 28B) and there was an observation of damaged cells due to toxicity when 
compared to the control lungs in the control Swiss Albino mice. The pathological 
observations in the figure 6.28B & 6.28D confirms that the fusion peptide is highly 
toxic to the animals. Further, the conserved sequences of all three flavivirus 
exhibited high toxic potential when challenged in Swiss Albino mice model. 
Finally, mice hyper immune sera was developed for evaluating the antigen 
(peptide) specific response in the treated mice.  
Figure 6.29: Dot ELISA. 1.JEV; 2. DENV; 3.NEG and 4.WNV 
 
 
 
 
 
 
 
 
 
Serum showed high titre of antibodies when collected from different time 
intervals.  There  was  no  color  development  in  the  pre  immune sera  and  also  in  the  
adjuvant sera. The sera were specific as they interacted only with viruses and not 
with other antigens such as Chikungunya, HSV, Influenza and Measles presented in 
the figure 6.29. The Dot ELISA was developed and presented in the figure 6.29. 
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DISCUSSION 
 
Flavivirus causing Acute Encephalitis Syndrome (AES) is a major public 
health problem in India which mainly affects the children and young adults. The first 
major outbreak was in West Bengal in 1973 involving 700 cases and over 300 
deaths. The AES is primarily caused by falvivirus. The group within the flavivirus 
genus with the largest number of viral species transmitted by mosquito vectors. 
These species include the Dengue virus (DENV), Japanese Encephalitis Virus 
(JEV), Myovascular Encephalitis Virus (MVEV), St. Louis Encephalitis Virus 
(SLEV), West Nile Virus (WNV), Yaounde virus, Cacipacore virus, Koutango virus, 
and Usutu virus. Among the above viruses the JEV, DENV and WNV were 
predominantly spread by the mosquito vector271. Dengue is caused by 4 genetically 
related but antigenically different viruses, and although it is uncertain where DENV 
evolved, maintenance of all 4 serotypes in enzootic cycles in Africa suggests that a 
progenitor virus most likely originated in Africa130. Aedesaegypti mosquitoes, the 
principal DENV vector, originated in Africa and spread to other countries in Africa 
and other tropical countries in the 17th and 18th centuries271,272.  
Several other Aedes species mosquitoes including Ae.albopictus, Ae. 
africanus, and Ae. luteocephalus are  found  in  Africa  and  are  potential  DENV  
vectors130 the ‘domesticated’ form is rarely found more than hundred from human 
habitation and feeds almost exclusively on human blood. West Nile virus is also an 
Arbovirus of the flavivirus family and is similar to other arthropod-borne 
flaviviruses that cause encephalitis, such as St Louis encephalitis, Japanese 
Polynesia virus, and Murray Valley virus.  
The JE and WNV is transmitted by female mosquitoes, usually the Culex 
species and birds serve as amplifying host272. Patients in whom WNV is suspected 
can have either serum or cerebrospinal fluid examined for immunoglobulin M 
antibodies to WNV. The mortality rate for WNV in hospitalized patients is estimated 
to be between 10% and 15%; patients with both encephalitis and weakness have a 
mortality rate of approximately 30%273. Individuals recently infected with or 
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vaccinated against similar viral illnesses such as yellow fever, Japanese Encephalitis 
or Dengue can have false positive reactions for WNV274 which are included in AES 
cases. 
Dengue had traditionally been known to be a disease of high population 
dense tropical urban areas275,276. The proportion of rural and urban patients among 
those testing antibody positive more or less paralleled the rural-urban ratio of 
enrolled patients indicating that Dengue transmission is occurring equally in  
rural and urban areas. Over the last One-two decades there are increasing  
reports of Dengue cases and outbreaks from rural areas in Southern and Western 
India273,277-282.  A single  study  from North  India  reports  on  outbreak  of  DF in  rural  
Haryana283. These outbreaks were investigated in a small number of patients with 
Dengue antibody estimations. Therefore, the present study is focused to investigate 
the epidemiology and molecular characterization of JEV, DENV and WNV. These 
viruses vary widely in their ability and characteristics to infect human and animal 
species. Serological studies identified the Japanese Encephalitis (JE) virus as one of 
the key virus to cause AES mortality. In the year 1978 and 2007, over 100,000 cases 
of  AES  with  a  case  fatality  rate  (CFR)  of  almost  33%  were  reported  from  13  
different  states.  It  was  widely  presumed  that  JE  was  the  predominant  etiological  
agent in these outbreaks284. 
The year wise AES cases were studied from 2011 to 14, which totally 
included 2559 susceptible AES cases were investigated for the screening of JE, 
DENV and WNV viruses. Amid the suspected cases 127 cases were confirmed 
positive cases for JE IgM antibodies, 60 cases were positive for Dengue IgM 
antibodies and 13 cases were positive for WNV IgM antibodies. Further, the 
epidemiological studies indicate that there is an increase in the susceptible cases 
from 2011 to 2014. The number of positive cases were highly significant in the year 
2013 followed by 2014.  
The age wise distribution of the AES case study demonstrated that the 
pediatric age group ranged between 0-12 years revealed higher positivity than the 
rest  of  the  other  age  groups.  Among the  positivity  of  AES cases,  the  JEV,  DENV 
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and WNV viruses indicated high positivity in the year 2012. Similarly the confirmed 
positive cases of serum samples were further investigated in CSF samples. Higher 
percentage positivity were revealed in both JEV and DENV in the year 2012. 
Approximately 2 billion people live in countries where JE presents a significant risk 
to humans, particularly in China and India, with at least 700 million potentially 
susceptible children285. In worldwide thirty-five thousand to 50,000 cases of AES - 
JEV were identified each year with upto 10,000 deaths.  
The JEV is the most common arbovirus causing human disease and the most 
frequent cause of childhood encephalitis in the endemic regions285,286. Encephalitis 
can only be said to have occurred when a histological diagnosis is available279,284. 
Several studies, however, had diagnosed encephalitis on indirect evidence, including 
absence of other explanations for encephalopathy, isolation of virus in CSF or its 
serological evidence, CSF pleocytosis, or focal neurological signs275.  
The district wise distribution revealed that Dengue occurred uniformly in the 
catchment area without areas of predilection. In the present study, the incidence of 
JEV, DENV and WNV causing AES in the various districts of Tamil Nadu was 
investigated during the period of 2011 to 14. The study revealed that the widespread 
JEV and DENV infection by vector transmission highly occurred in areas such as 
Chennai, Thiruvallur and Kanchipuram districts. In the same way the WNV were 
highly reported in the areas of Thiruvannamalai, Chennai and Thiruvallur districts.  
All the reported areas were statistically significant and it was confirmed by 
the positive cases in subsequent areas. Season wise distribution were investigated 
during the study period between 2011 to 2014. The study revealed that the JE virus 
significantly reported as higher positivity in all the seasons except premonsoon. The 
Dengue virus explored highly in the North East and South West monsoon of 2011 to 
2014 whereas West Nile virus explored only in the South West monsoon and not in 
the rest of the seasons. 
 Globally, there is seasonality variation reported in other countries. For 
example, the Eastern China, where JE cases were reported in summer season277. 
Higher number of cases may be due to creation of many breeding sources for Culex 
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mosquito species in paddy fields and might be responsible for the increased risk of 
JE cases277,278.  Sero  epidemiological  surveys  were  also  conducted  in  winter  season  
(that is, November, 2005 to January, 2006) where 7.6% of JE cases were reported. 
JE cases during winter season may be due to second phase cultivation period of 
paddy when there were sufficient numbers of mosquito breeding places. Similar 
kinds of data were also reported on JE cases during winter season278.  
Based  on  these  study  reports,  JE  tends  to  be  endemic  and  cases  occur  
sporadically throughout the year with a peak after the start of the rainy season. 
Hence, it is assumed that climate variability has a direct influence on JE cases279. 
Temperature (22 to 34°C) and relative humidity (42.7 to 69.6%) were ambient 
conditions to facilitate the higher mosquito density as well as JE virus replication 
which in turn would be responsible for the occurrence of JE cases287. 
Month wise data of AES cases revealed that the higher monthly infective rate 
values were reported in the September to November and extended up to December 
and was least during summer season of year. This suggests that variations in 
infection during these different seasons are mainly responsible for transmission of 
vectors in humans. Thus, temporal changes might have greatly impacted the 
efficiency of arboviral transmission in nature, which would have significant 
epidemiological importance. Further it is noticed that minimum and maximum 
temperature were found to be positively correlated with number of AES cases in 
rainfall and relative humidity. It is also noticed that the average rainfall during the 
study period was 70.5mm and relative humidity was between (45.6 to 70.1%). Even 
though, with this low rainfall and low relative humidity, occurrence of many JE 
cases were noticed, and this may be due to the availability of sufficient number of 
breeding places for mosquitoes and suitable temperature for development and 
transmission of JEV and DENV virus. 
More number of patients belonged to the age group of 11 to 20 years 
followed by 21 to 30 years which was consistent with studies conducted in different 
parts of India288,289. In a study conducted in Delhi 21 to 30 years age group was most 
commonly affected and another study conducted in Kanpur, showed 0 to 15 years 
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age group to be commonly affected290,291. In this retrospective study, DF was found 
to  be  the  most  common  presentation  which  was  similar  to  a  study  conducted  in  
Delhi292. It is an established fact that complications like DHF and DSS occur mainly 
in cases with secondary infections due to antibody mediated immune enhancement, 
cross reactive T–cell response with activation of TH-2 lineage cell and stimulation 
of soluble factors293. In the present study the age wise distribution of the AES cases 
were comparatively high in the pediatrics and the young age group of 13-25. The 
other age groups were not significant to the positivity of AES investigation. 
This longitudinal study revealed a steady increase of JE cases from 2011 to 
2014, indicating a possible public health threat in the near future. The incidence of 
JEV and DENV infection was relatively high during South West and North East 
monsoon  and  it  strongly  depends  on  rainfall,  humidity  and  temperature  as  well  as  
the paddy cultivation. Effects of climate change on rainfall, temperature and other 
climatic variables may increase the vector populations and risk of JEV infection, 
especially in temperate regions like India. Apart from these factors, availability of 
high mosquito abundance, virus reservoirs, virus infected mosquitoes, development 
of resistance to effective insecticides, rapid globalization, population explosion and 
global climate change have also influenced the endemicity of this disease281. As of 
now, no disease surveillance studies have been carried out in this region, and this 
study is to make an attempt to understand the disease scenario and vector dynamics 
in relation with weather variables.  
Further the maximum number of Dengue cases were reported in the month of 
September which indicated an active viral transmission during monsoon and post-
monsoon period as reported earlier282,284. A higher occurrence of Dengue infection 
was noted among females which is similar to the present study conducted in 
Chennai294. However, this was discordant with other studies where a male 
predominance was noticed. Similarly in the present study the gender wise analysis 
indicated that the male population of the AES cases was highly susceptible for all 
the flaviviruses. The overall statistical analysis of JEV, DENV and WNV revealed 
the higher numbers of positive cases were occurred in the male population when 
compared to the female population. 
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Further the molecular characterization of JEV, DENV and WNV were 
genetically sequenced with the non structural protein gene 5 and polyprotein gene. 
The PCR amplicons of the non structural protein gene 5 and polyprotein genes were 
sequenced and detected for the genotypic characterization. The study indicates that 
the JEV was characterized by non structural region of 5 with 241bp and notably it 
was developed as markers for diagnosis. Similarly the DENV were characterized by 
two genotypes which include D3 and D4. The D3 genotype of DENV was 
characterized by 288bp and D4 genotype of DENV was characterized by 260bp. The 
WNV were characterized by the 396bp polyprotein gene.  
Similarly recent reports identified the presence of WNV infection in 
Southern India by real-time RT-PCR and RT- LAMP assays and found 
neuroretinitis and retinitis to be the most common ocular findings. The study 
inferred that the majority of patients had a good prognosis. Real-time RT-PCR and 
RT-LAMP assays can be used as diagnostic tools, and the RT-LAMP assay is more 
cost-effective with the same effectiveness as RT-PCR and real-time RT-PCR. Real-
time RT-PCR assays using either probes with Taqman technology or SYBR Green 
have been developed for the detection of WNV infection295,296. Recently, other PCR-
based methods such as the RT-LAMP assay have been developed by targeting the 
envelope gene of WNV. The RTLAMP assay is a novel method of gene 
amplification that amplifies nucleic acid with high specificity, efficiency and 
rapidity,  under  isothermal  conditions,  with  a  set  of  six  specially  designed  primers  
that recognize eight distinct sequences of the target297. 
Haemagglutination (HA) and Haemagglutination Inhibition assays (HI) have 
been widely used for the detection of arthropod-borne viruses and the antibodies 
developed to these viruses, respectively298. These  assays  exploit  the  ability  of  the  
envelope glycoprotein to bind and agglutinate avian erythrocytes so that they form a 
visible lattice in a U-bottom microtitre plate. In the HI assay, antibodies from 
infected individuals prevent the agglutination of the erythrocytes, which 
subsequently form a pellet.  
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While the HAI assay was used extensively in the past for virus serology, this 
technique has now been largely superseded, in favour of assays with better 
sensitivity and specificity, but is still used in some instances for surveillance. The 
advantages of HAI assays were providing avian red blood cells are available, the 
assays can be performed with minimal training and equipment and the antigen used 
could be inactivated by a simple extraction process. However, as for PRNT, there is 
a requirement for the simultaneous assessment for viruses endemic for the area and 
multiple different pH buffers are required for each different antigen.  
In the present study the flavivirus isolated samples were subjected for 
Haemagglutination in different pH. The study reveals that the optimum pH for the 
Haemagglutination of the JEV, DENV and WNV. JEV was well agglutinated at pH 
6.2. Similarly the Dengue and West Nile viruses were agglutinated well at pH 6.4. 
Further the study indicated that the HA viral titre of JE viruses was optimally 
observed as 1:128, Dengue viruses demonstrated the optimum titre of 1:256 and 
West Nile virus as 1:32. 
The  Immunofluorescence  assay  (IFA)  can  be  used  to  differentiate  the  IgM  
and IgG responses to viral infection. It involved incubation of patient serum with 
glass slides, upon which were fixed virus infected cells. The benefit of this assay is 
that prefixed slides can be stored at 4°C and a BSL-3 facility is not required to 
perform the assay and results can be obtained quickly, particularly due to the 
commercialization of IFA kits (e.g., Focus Diagnostics Arbovirus IFA).  
However, cross-reactivity of immune antibodies with closely related viruses 
can impair the accuracy of the diagnosis and there is a requirement for a fluorescent 
microscope to evaluate the results. In the study JEV, DENV and WNV isolates were 
confirmed by IFA and illustrated as apple green colour under immunofluorescence 
microscope. The negative of all the viruses were cherry red colour due to the non 
adherent binding of specific IgM antibody fluorescent tag. Further in the study it 
was standardized as the dilution of 1:10 stains good fluorescence intensity with less 
noise in the background. This observed dilution was further applied to the studies 
with the viruses isolated from clinical samples. 
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Nucleic acid-based assays offer rapid and specific detection and serotyping 
of viruses are gradually replacing serological and culture techniques. These methods 
include nested RT-PCR real-time RT-PCR, loop-mediated isothermal amplification, 
nucleic acid sequence-based amplification and Taqman assays299. 
In the present study the molecular phylogeny, of JEV isolates i.e. 
[Genbank :KJ947880] were very closer to the clade of Indian sequences 
gi|496909/India/2005/envelope, gi|239633849/India/2009/envelope and gi| 
289466091/ India/2011/envelope. This showed that closer clustering, even though 
all of 2 isolates were from a geographically distant location or different districts of 
the  state  of  Maharashtra,  Kerala  and  Assam.  This  indicated  similarities  among the  
isolates circulating in the 2 consecutive years 2009 and 2011.  
Moreover, based on the present study, stated that there had been 
simultaneous circulation of JEV strains in India. Similarly the Dengue strains were 
highly close to the clade of Taiwan (gi/25992032/Taiwan/2006/Polyprotein) 
(gi/25992032/Taiwan/2006/Polyprotein), Peru (gi/19071812 Peru/2002/capsid) and 
Srilanka (gi 164654854 Srilanka/2015/Anchored). The above clade were highly 
close to the KIPM KJ947880 sequences. In the West Nile virus the phylogeny 
indicated that WNV 1 and 2 were highly homologous with the clade of  
Madagascar (gi|58618099/Madagascar/2006/polyprotein) and USA (gi|27735298/ 
USA/2012/unnamed). Further the strain was also homologous (94%) with Israel 
(gi|290246783/Israel/2011/polyprotein) and USA gi|158516889/USA/2015/ 
unnamed). 
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SUMMARY 
 
Acute encephalitis syndrome (AES) is a clinical condition caused by 
infection with viruses such as Japanese Encephalitis virus (JEV), Dengue viruses 
and West Nile viruses or other infectious and noninfectious causes. Acute 
Encephalitis Syndrome (AES) causes a great public health problem in India, 
occurring both in epidemics and sporadically. Globally, the magnitude of problem 
has been estimated to be around 50,000 cases and 10,000 deaths annually300. 
A confirmed etiology is generally not required for the clinical management 
of AES. Thus, surveillance of the above viral infections in India has focused on 
identifying AES cases rather than JEV, DENV and WNV cases. AES in India, 
especially Northern India, as per definition of WHO301,302 encompasses several other 
illnesses; it has malaria, enteric encephalopathy, tubercular meningitis, Dengue with 
neurological manifestations, scrub typhus, bacterial meningitis, etc. It surely is a 
mixed pot. 
Japanese Encephalitis, an arboviral infection, is a serious public health 
problem in the Asian region. Globally, it affects 67,900 people per year, of which 
about a third are likely to die. The change in climate, ecological imbalance, and 
population growth together with related demands for change in agriculture and 
animal rearing practices have recently intensified its threat along with that of other 
viral encephalitis. However, many nations still struggle for disease burden data on 
acute encephalitis that can be used to plan prevention and control strategies. Man is 
the accidental host and dead end for the transmission of the disease303,304.  
In Tamil Nadu, the first clinical case of JE was observed in 1955 at Vellore 
in India305. The first major Outbreak of JE occurred in 1973 in Bankura & Burdwan 
districts of West Bengal. In1976, wide spread outbreaks were reported from Andhra 
Pradesh, Assam, Karnataka, Tamil Nadu, Uttar Pradesh and West Bengal. The 
sources of virus may be different causing almost similar symptoms. Hence, all JE 
cases are being reported under Acute Encephalitis Syndrome (AES) after the 
outbreak of JE in Gorakhpur and Basti divisions in Eastern Uttar Pradesh during 
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2005 302. It is a disease of major public health importance because of its epidemic 
potential and high case fatality rate. The highly affected states include Andhra 
Pradesh,  Assam,  Bihar,  Goa,  Karnataka,  Manipur,  Tamil  Nadu,  Uttar  Pradesh  and  
West Bengal.  Outbreaks of JE, Dengue and WNV usually coincide with monsoons 
and post- monsoon period when the vector density is high. Early management of the 
disease is essential, because there is no specific treatment. High vaccine coverage 
along with active surveillance is essential.  
The ultimate objective is to prevent the disease occurrence by early 
diagnosis, implementation of effective control measures, high vaccine coverage with 
strong and active surveillance system306.  Therefore  in  the  present  study  the  sero  
surveillance of AES including viruses such as Japanese Encephalitis, Dengue and 
West Nile viruses were investigated in to 14 districts of TamilNadu viz., Chennai, 
Thiruvallur, Kanchipuram, Thiruvannamalai, Villupuram, Cuddalore, Thanjavur, 
Ariyalur, Perambalur, Vellore, Trichy, Madurai, Thirunelveli and Erode. 
Among the districts, the maximum positive AES cases of JE and Dengue 
were reported in Chennai, Thiruvallur and Kanchipuram district of Tamil Nadu. The 
higher positive AES cases of West Nile virus were explored in Thiruvannamalai, 
Chennai and Thiruvallur. The age wise distribution of AES cases were analyzed and 
divided like 0-12, 13-18, 19-35, 36-55 and above 55. The prevalence in different age 
groups were statistically analyzed and represented in the figure by standard error 
mean. Among the age groups, the positivity was predominantly seen in the pediatric 
age group in all the years. Few positive cases were observed in young adults. 
 In the years 2013 and 2014, the high positivity was observed in adults and 
elder age groups. The total suspected cases were statistically analyzed using linear 
regression in different periods from 2011 to 2014. The linear regression analysis 
indicates that there is an increase in sample size and the total number of suspected 
cases was linearly raised from 2011 to 2014. In comparison of the three viruses in 
AES cases the Dengue occupies higher number of samples. The sample size of all 
the viruses in AES in the study period 2011-14 was in the order of JEV > 
Dengue>West Nile viruses. But the regression scatter plot in reveals that all the 
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three flaviviruses were increase in the susceptible cases. The multiple comparison 
analysis of the study period infers the higher number of positivity was observed in 
2013 followed by 2014.The Post hoc Dunnet statistical analysis inferred that there 
was significant difference was found within the groups and there was no significant 
difference between the groups. The one way ANOVA analysis of different age 
groups were analyzed in different periods of the year. The mean difference was 
significant in all the age groups with degrees of freedom 0.05 level. 
The  season  wise  distribution  of  cases  was  statistically  analyzed  for  their  
epidemiological characterization of the AES in the study period. The Japanese 
Encephalitis virus expresses predominantly highest positive cases in all the seasons 
except premonsoon. The Dengue viruses have highest positive cases in the South 
West and North East monsoon seasons. Less number of susceptible cases occurs 
during the winter and premonsoon seasons. The Positive cases of West Nile virus is 
highly  occurring  in  the  south  west  monsoon  than  the  other  seasons.  The  age  wise  
and  gender  wise  analysis  were  done  in  the  study  period.  It  was  observed  that  the  
male cases were high positive and susceptible than the female cases. Especially the 
age group of pediatrics (0-12) and young age (12-25) group indicated high positivity 
than the rest of the other age groups. 
The year wise AES Positive cases were studied from 2011-14, totally 2559 
susceptible AES cases were investigated for the screening of serum ELISA in JE, 
DENV and WNV viruses. Amid the susceptible cases 127 cases were confirmed 
positive cases for JE IGM antibodies, 60 cases were positive for serum IGM 
antibodies and 13 cases were positive for WNV IGM antibodies.  
Further the epidemiological studies indicate that there is an increase in the 
susceptible cases from 2011-14. But the number of positive cases was highly 
significant in the year 2012. Because less number of cases were screened in 2012, 
but  high  number  of  positives  were  confirmed.  Similarly  CSF  cases  were  screened  
totally in 1792 samples. High numbers of positivity were revealed in both JEV and 
DENV than WNV. Further the viruses were characterized molecularly and 
genotypically for developing new markers for diagnosis. The positive samples were 
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cultured in the Vero cell lines. Then it the specificity and sensitivity of the cell 
passages were characterized. 
The isolated JE virus were more sensitive in the early passages of 2 and 4, 
rest of the passages were less sensitive and specificity. Similarly, the Dengue virus 
was more attuned in the late 6th passage. But the West Nile virus was highly 
compatible in the 5th passage of Vero cell lines. 
The Virus isolated samples were then preceded for Haemagglutination in 
different pH (6, 6.2 and 6.4). The optimum pH of the JE virus was 6.2, Dengue and 
West Nile viruses were agglutinated well at the optimum pH of 6.4. The viral titre of 
JE viruses was observed as 1:128. Dengue viruses revealed the optimum titre of 
1:256 and west Nile virus 1:32. For the rapid diagnosis, Immunofluroscence assay 
was attempted in the JEV, DENV and WNV.  
Further in the study it was standardized as the dilution of 1:10 stains good 
fluorescence intensity with less noise in the background. This observed dilution was 
further applied to the studies with the viruses isolated from clinical samples. Further 
in the present study, the molecular phylogeny of JEV isolates i.e. [Genbank 
:KJ947880] were found to be closer to the clade of Indian sequences 
gi|496909/India/2005/envelope, gi|239633849/India/2009/envelope and gi| 
289466091/India/2011/envelope. This indicates that closer clustering, even though 
all of 2 isolates were from a geographically distant location or different districts of 
the state of Maharashtra, Kerala and Assam. This demonstrated that similarities 
among the isolates circulating in the 2 consecutive years 2009 and 2011.  
Moreover, based on the present study, stated that there had been 
simultaneous circulation of JEV strains in India. Similarly the Dengue strains were 
highly close to the clade of Taiwan (gi/25992032/Taiwan/2006/Polyprotein) 
(gi/25992032/Taiwan/2006/Polyprotein), Peru (gi/19071812 Peru/2002/capsid) and 
Sri Lanka (gi 164654854 srilanka/2015/Anchored). The above clades were highly 
close to the KIPM KJ947880 sequences.  
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In the west Nile virus the phylogeny indicated that WNV 1 and 2 were 
highly homologous with the clade of Madagascar (gi|58618099/ Madagascar/ 
2006/polyprotein) and USA (gi|27735298/ USA/2012/unnamed). Further the strain 
was also homologous (94%) with Israel (gi|290246783/Israel/2011/polyprotein) and 
USA gi|158516889/ USA/2015/unnamed). Finally, this indicates that the same type 
of West Nile strains was circulated in India. Further the strains were exposed due to 
the patients recently migrated in the homologues countries and spread in Southern 
part of India. 
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CONCLUSION 
 
¾ The role of three flaviviruses namely, JEV, DENV and WNV viruses as 
causative agent of Acute encephalitis syndrome during the period 2011-
2014, their epidemiology and molecular characterization were analyzed in 
depth. 
¾  Among the three flaviviruses screened, JEV was found to be most prevalent, 
followed by DENV and then WNV. 
¾ The pediatric age group (0-12 yrs) showed a high positivity for flaviviruses 
followed by the young and adolescent age group of 13-25 years. 
¾ Out of the 14 districts screened the district Chennai, Thiruvallur, 
Thiruvannamalai and Kanchipuram districts had high prevalence of AES 
viruses such as JEV/DENV/WNV during the study period of 2011-2014. 
JEV infection was highest in Chennai, Thiruvallur and Kanchipuram 
districts. DENV infections were found to be high in Thiruvannamalai 
districts. WNV causing AES in Tamil Nadu was found to be high in Chennai 
district followed by Kancheepuram. . 
¾ Season  wise  distribution  of  the  study  demonstrates  that  the  JEV  positivity  
was widespread in all the seasons more during the monsoon and post 
monsoon season, but low degree was positivity was seen during summer 
months also showing residual activity of mosquitoes. The Dengue virus 
positivity during the months of September, October and elevated in 
November. In the districts along the Western ghats, like Theni, 
Kanyakumari, Thirunelveli DENV positivity started early, from end of June 
onwards raising gradually and peaking in November and December months.  
¾ These districts receive rains early due to the South West monsoon and their 
positivity increases with rains and post monsoon months have high positivity 
due to water stagnation and storage. In the Northern district of Tamil Nadu 
the increase in positive cases, mainly due to North East monsoon which 
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starts from September end onwards. All this indicates public health activity 
should increase before the onset of monsoon with round the year public 
health department educate and create awareness on these infections.  
¾ WNV infections were prevalent in the Northern districts and the early start of 
monsoon resulting in increase in their positivity.  
¾ Month wise data of AES cases revealed that the higher MIR values were 
reported in the September to November and extended up to December and 
was least during only in summer season. 
¾ During the study period, there is an increase in the susceptible cases from 
2011-14. But there was a marked raise in the positivity of flavivirus 
infections in 2013 and 2014, possibly better health care facilities referring 
more cases for testing. 
¾ Sera diagnosis indicated the prevalence of JE, showed positivity in the 
pediatric age group predominantly but during the course of the study there 
was an increase of JEV infections among the adult population. 
¾ The molecular characterization of JEV, DENV and WNV was characterized 
by  RT –PCR and nucleotide  sequencing.  On sequence  analysis  of  JEV,  the  
strains were found to be similar to the isolates similar to different districts of 
the state of Maharashtra, Kerala and Assam strains. 
¾ WNV were very close to the clades of Madagascar and USA. strains on 
sequence analysis. Among DENV Subtype were predominant homologues to 
Taiwan, Peru and Srilanka. The molecular phylogeny of JEV isolates were 
homologues to Maharashtra, Kerala and Assam circulating in the 2 
consecutive years 2009 and 2011 indicating that no new JEV strains were in 
circulation in Tamil Nadu. 
¾ But the Dengue and West Nile isolates were homologues to Taiwan, Peru, 
Srilanka and USA and Madagascar. There is no mutant strain found in the 
isolates. 
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¾ The IFA assays were standardized for the simultaneous screening of JEV, 
DENV and WNV among AES cases. This provides a rapid diagnosis of 
flaviviruses especially in tertiary care setting. 
¾ Standardization of RT-PCR, Peptide ELISA and Dot ELISA were 
developing new insight in marker development for JEV, DENV and WNV 
Diagnosis.  
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RECOMMENDATION 
 
 Vector control measures should be implemented for effective management 
and prevention of viral transmission such as Japanese Encephalitis, Dengue and 
West Nile viruses. Reducing contact between humans and potentially infected 
mosquitoes is the only way to reduce infection rates, morbidity and mortality due to  
viral infection. Personal protective measures that should reduce the risk of infection 
by avoiding outdoor activity in areas with potentially infected mosquitoes, using 
mosquito repellents, eliminating conditions that support mosquito breeding (eg, 
eliminate standing water, clean rain gutters); maintaining window and door screens, 
wearing long-sleeved shirts and long pants in outdoors. 
Vaccination programme should be advised to public and create awareness 
among the public on the severity of viral diseases such as JE, Dengue and West Nile 
viruses. Available Vaccinations such as JE virus should be reach people living in 
susceptible areas for effective management and prevention. Other viruses such as 
Dengue and WNV infected patients should be quarantined if affected and necessary 
steps should be taken for treatment and prevention. Department of public health and 
medical education should take necessary steps for controlling vectors and educate 
the people frequently through medias in the highly susceptible places. Finally 
government should support and strengthen the laboratories for surveillance and 
incidence of flaviviruses (JE, Dengue and WNV) in all the reported areas. 
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